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Zusammenfassung
Zusammenfassung
Die Messung von Proteinen aus Patientenproben ist von überragender Bedeutung
für die medizinische Diagnostik. Neben den klassischen Enzyme-linked Immun-
osorbent Assays in der Labormedizin findet Proteinanalytik in Form der MALDI-
TOF-Massenspektrometrie neuerdings maßgeblichen Einsatz zur molekularen
Speziesdiﬀerenzierung in der Mikrobiologie. Die Massenspektrometrie eröﬀnet
dabei vollkommen neue Perspektiven für die medizinische Diagnostik, indem sie
die Quantifizierung aller in einer Zelle oder einem Organismus vorkommender
Proteine, das sogenannte Proteom, anstrebt. Der technologische Fortschritt der
vergangenen Jahre ermöglicht es seit kurzem, ein solches Proteom innerhalb weni-
ger Stunden zu messen.
In dieser Arbeit präsentiere ich die Bestimmung des humanen Speichelproteoms
von acht gesunden Individuen zu zwei Tageszeiten mittels Massenspektromet-
rie basierter Proteomik. Die erworbene Proteindatenbank gewährt umfassende
Einblicke in die Proteinzusammensetzung und die Dynamik des menschlichen
Speichels und stellt mit mehr als 5000 Proteinen das tiefste bislang gemessene
Proteom einer Körperflüssigkeit dar. Große Teile dieses Proteoms lassen sich
bereits in einem beschleunigten Verfahren mit nur vier Stunden gesamter Ana-
lysezeit erheben und erscheinen deshalb attraktiv zur Nutzung in der klinischen
Diagnostik. Dabei wird auch das humane Speichelproteom mit dem humanen
Plasmaproteom verglichen und daraus ergibt sich der Schluss, dass die Pro-
teinkonzentrationen zwischen Speichel und Plasma kaum korreliert sind. Damit
erscheint es für zahlreiche Proteine nicht möglich, ihre Plasmakonzentrationen
anhand der Konzentration im Speichel abzuschätzen.
In einem zweiten Schritt wird die direkte Messung des oralen Mikrobioms mit
Massenspektrometrie basierter Proteomik vorgestellt. Im Gegensatz zur derzeit
in der Mikrobiologie verwendeten MALDI-TOF-Massenspektrometrie benötigt
die hier gezeigte Methode keinerlei kulturelle Anzucht der gemessenen Bakter-
ien. Das könnte von großem Interesse für eine schnelle Erregerbestimmung und
Resistenztestung sein. Die Ergebnisse zeigen Proteinsignaturen von 50 bak-
teriellen Genera und erlauben eine quantitative Abschätzung ihrer Veränder-
ungen im Tagesverlauf. Eine Validierung dieser Bestimmung mit MALDI-TOF-
Massenspektrometrie und mit Daten des Human Microbiome Project ergibt eine
sehr gute Übereinstimmung. Damit stellt die Massenspektrometrie basierte Pro-
teomik eine komplementäre Methode zur Bestimmung des Mikrobioms dar. Die
kurze, kulturunabhängige Analyse begründet die Hoﬀnung, Mikrobakterien in
Zukunft noch schneller und präziser charakterisieren zu können.
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Abstract
Abstract
The measurement of proteins from patient samples is of outstanding significance
for medical diagnostics. Apart form classical Enzyme-linked Immunosorbent
Assays in laboratory medicine protein analysis has recently been increasingly
used in the form of MALDI-TOF mass spectrometry for the biotypization in
microbiology. Mass spectrometry opens new perspectives for medical diagnostics
allowing the quantification of all proteins in a cell or an organism, the so called
proteome. The technological progress in the last couple of years enables the
measurement of such a proteome within only a few hours.
In this thesis I present the human saliva proteome of eight healthy individuals
for two timepoints as determined by mass spectrometry based proteomics. The
acquired protein repository provides a comprehensive insight into the protein
composition and dynamic of human saliva and represents the deepest body fluid
proteome measured to date comprising more than 5000 proteins. A large propor-
tion of this proteome can be obtained by a fast-track method of just four hours of
total measurement time rendering it appealing for clinical diagnostics. The com-
parison of the human saliva proteome and the human plasma proteome reveal
that the protein concentrations between saliva and plasma are hardly correlated.
Consequently, it does not seem to be possible to determine the concentrations of
many proteins in plasma from their concentration in saliva by proxy.
In a second step the direct measurement of the oral microbiome by mass spec-
trometry based proteomics is presented. By contrast to the currently employed
MALDI-TOF mass spectrometry, the method introduced here does not require
any cultivation of the measured bacteria. This might be of great interest for the
fast species diﬀerentiation and for resistance testing. The results show protein
signatures of 50 bacterial genera and allow a quantitative estimate of their alter-
ations during the day. A validation of these measurements with MALDI-TOF
mass spectrometry as well as with data from the Human Microbiome Project
reveal good agreement. Hence, mass spectrometry based proteomics represents
a complementary approach to determine the microbiome. The short, culture
independent analysis nourish hope that it will be possible to characterize mi-
crobacteria even faster and more precisely in the future.
v

Contents
Contents
Abbreviations ix
1 Introduction 1
1.1 The nature of the proteome . . . . . . . . . . . . . . . . . 1
1.2 Mass spectrometry-based proteomics . . . . . . . . . . . . . . 2
1.3 MALDI-TOF in clinical microbiology. . . . . . . . . . . . . . 8
1.4 Scope of the project . . . . . . . . . . . . . . . . . . . . 10
1.5 Body fluid proteomics . . . . . . . . . . . . . . . . . . . . 12
1.6 The human saliva proteome . . . . . . . . . . . . . . . . . 13
2 Material and Methods 15
2.1 Study cohort . . . . . . . . . . . . . . . . . . . . . . . 15
2.2 Sample collection and preparation . . . . . . . . . . . . . . . 16
2.3 Protein database . . . . . . . . . . . . . . . . . . . . . . 17
2.4 Protein identification and quantification. . . . . . . . . . . . . 17
2.5 Data analysis . . . . . . . . . . . . . . . . . . . . . . . 19
2.6 Comparison to sequencing data . . . . . . . . . . . . . . . . 20
2.7 Comparison to MALDI-TOF mass spectrometry . . . . . . . . . 21
3 Results 23
3.1 In depth quantification of the human saliva proteome . . . . . . . 23
3.2 Dynamics of the saliva proteome . . . . . . . . . . . . . . . 27
3.3 Identification of the oral microbiome by proteomic means . . . . . . 28
3.4 Quantification of the oral metaproteome . . . . . . . . . . . . 33
3.5 Interindividual variation and dynamics of the oral microbiome . . . 35
4 Discussion 37
4.1 Significance of MS based saliva proteomics and determination of the
oral microbiome . . . . . . . . . . . . . . . . . . . . . . 37
4.2 Technological challenges for clinical proteomics . . . . . . . . . . 38
4.3 Perspectives for clinical proteomics. . . . . . . . . . . . . . . 39
vii
Contents
Appendix 43
A Multiplying sequencing speed using Trapped Ion Mobility Mass
Spectrometry 43
A.1 The problem of inaccessible peptide species in data-dependent LC-
MS/MS . . . . . . . . . . . . . . . . . . . . . . . . . 43
A.2 Instrument characteristics of a TIMS-QTOF mass spectrometer . . . 44
A.3 Principle of Parallel Accumulation-Serial Fragmentation . . . . . . 46
A.4 Realization of Parallel Accumulation-Serial Fragmentation . . . . . 48
A.5 Parallel Accumulation-Serial Fragmentation in the analysis of a com-
plex peptide mixture . . . . . . . . . . . . . . . . . . . . 49
A.6 Relevance of Parallel Accumulation-Serial Fragmentation for clinical
proteomics . . . . . . . . . . . . . . . . . . . . . . . . 51
A.7 Materials and Methods of Parallel Accumulation-Serial Fragmentation 52
B Eﬀects of sustained weight loss on the human plasma proteome 53
B.1 Evaluating weight loss eﬀects on the body from a systems perspective . 53
B.2 Study design and plasma proteomics analysis . . . . . . . . . . 54
B.3 Interindividual variation of the plasma proteome . . . . . . . . . 55
B.4 Impact of weight loss on the plasma proteome . . . . . . . . . . 57
B.5 Eﬀects of weight loss on the apolipoprotein profile . . . . . . . . 59
B.6 Eﬀects of weight loss on inflammatory proteins . . . . . . . . . . 61
B.7 Clinical significance of plasma proteomics changes upon weight loss . . 62
B.8 Materials and Methods of the plasma proteome project . . . . . . 64
C Supplementary material 67
C.1 Additional figures of the saliva proteome project . . . . . . . . . 67
C.2 PASEF analysis of 40 precursors from a complex peptide mixture . . 69
References 71
viii
Abbreviations
Abbreviations
ADH Alcohol dehydrogenase
APCS Serum amyloid P-component
APO Apolipoprotein
ATRN Attractin
BMI Body mass index
BSA Bovine serum albumin
CF Complement factor
CID Collision induced dissociation
CRP C-reactive protein
CV Coeﬃcient of variation
EF Enrichment factor
ELISA Enzyme-linked Immunosorbent Assay
ESI Electrospray ionization
FDR False discovery rate
FWHM Full width half maximum
HDL high density lipoprotein
HMP Human Microbiome Project
HPLC High performance liquid chromatography
IMS Ion mobility spectrometry
ITIH3 Inter-alpha-trypsin inhibitor heavy chain H3
iTRAQ Isobaric tags for relative and absolute quantitation
LBP Lipopolysaccharide-binding protein
LC Liquid Chromatography
LDL low density lipoprotein
LFQ Label free quantification
MALDI Matrix-Assisted Laser-Desorption/Ionization
ix
Abbreviations
MS Mass spectrometry
NRP1 Neuropilin-1
ORM Alpha-1-acid glycoprotein
PASEF Parallel Accumulation-Serial Fragmentation
PCA Principle component analysis
PCR Polymerase chain reaction
PON1 Serum paraoxonase 1
PRG4 Proteoglycan 4
QTOF Quadrupole time of flight
SA Serum amyloid protein
SDB-RPS Styrenedivinylbenzene-Reversed Phase Sulfonate
SERPINA1 Alpha-1-antitrypsin
SERPINA3 Alpha-1-antichymotrypsin
SERPINA6 Corticosteroid-binding globulin
SERPIND1 Heparin cofactor 2
SERPINF1 Pigment epithelium-derived factor
SHBG Sex hormone-binding globulin
SILAC Stable isotope labelling with amino acids in cell culture
SWATH Sequential window acquisition of all theoretical mass spectra
TIMS Trapped ion mobility spectrometry
TMT Tandem mass tag
TOF Time of flight
x
1 Introduction
1.1 The nature of the proteome
A comprehensive understanding of the human body requires a detailed know-
ledge of its molecular constituents and their interaction in health and disease.
Over the course of the last century scientists made huge progress in the analysis
of biomolecules leading to sophisticated diagnostic tools and specific pharmacolo-
gical therapies for the diagnosis and treatment of diseases. Yet, the pathogenesis
of many diseases is only partially understood and for only few diseases specific
diagnostic markers are in place.
At present, the breakthroughs in genome sequencing stir hope that the com-
parison of genomes of diﬀerent individuals and of pathogens will revolutionize
medical diagnostics and treatment. While genome sequencing will almost cer-
tainly have a big impact on personalized medicine it should be noted that in
most of the cases genes only predispose for certain diseases. Ultimately, diseases
manifest themselves on the level of proteins. Not surprisingly, most laboratory
tests determine the level of a particular protein in a probe. While the DNA is
merely the construction plan, proteins are the executives of almost all cellular
functions. This is best illustrated by a caterpillar that turns into a butterfly -
both share the same genome, but they have a vastly diﬀerent morphology and
protein composition [1]. Similarly, diﬀerent cells in the human body vary greatly
in their size, shape and function despite the fact that most of them carry identical
copies of the genome.
The proteome is therefore defined in analogy to the genome as all the expressed
proteins under a given biological condition. This does not only include the
protein amount, but also their modification, location in the cell, interaction
partners and their turnover. Hence, the proteome is highly complex and dynamic.
Clearly, the proteome is the most relevant entity for the understanding of cellular
function and regulation. Proteomics - the study of the proteome - is a systems
biology approach to capture the properties of all the proteins of a system as
opposed to the investigations of individual gene products in classical molecular
biology.
Proteomics has not found widespread application in medical diagnostics yet -
with the exception of Matrix-assisted Laser-Desorption/Ionization time of flight
(MALDI-TOF) mass spectrometry (MS) that revolutionized biotypization of
bacteria and fungi. This is mainly due to the fact that the methodological rep-
ertoire to study the entire cellular proteomes in the form of mass spectrometry
based proteomics has only been developed recently.
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Measuring the protein composition of a tissue is challenging for two main rea-
sons. First, the dynamic range in protein abundance covers several orders of
magnitude, which makes it very diﬃcult not to lose signals from proteins with
low copy numbers. For example, Nagaraj et al. showed that the proteome of the
widely studied cell line HeLa encompasses 12000 proteins with a dynamic range
of six orders of magnitude [2]. Secondly, proteins cannot easily be replicated
by means of molecular biology in contrast to DNA which can be amplified by
polymerase chain reaction (PCR). Consequently, the first characterization of
the proteome of a free living organism was only achieved in 2008 for yeast [3].
In comparison, the first whole genome of Haemophilus influenzae was already
sequenced in 1995 [4].
While the genome is less complex than the proteome, genome sequencing meth-
ods are much more mature than proteomics analysis methods. The transcrip-
tome represents an intermediate layer of complexity and can be well studied by
means of molecular biology. However, despite the common determination of the
transcriptome to map regulatory cellular changes it should be noted that the pro-
teome and the transcriptome are only moderately correlated with a correlation
coeﬃcient of r= 0.7 or less [5]. Despite the challenges to determine proteomes,
huge progress has been made in mass spectrometry based proteomics in the last
couple of years. Entire cellular proteomes can now be measured in a matter of
hours using shotgun mass spectrometry [6, 7]. In 2014 two groups independently
published nearly complete drafts of the human proteome using electrospary ion-
isation (ESI)-MS based shotgun proteomics [8, 9]. Although their bioinformatic
analysis was criticized by the proteomics community [10], the results show that
ESI-MS based proteomics might soon be applicable for clinical diagnostics.
1.2 Mass spectrometry-based proteomics
The choice of the analysis method in MS-based proteomics depends on the sci-
entific question to be addressed. Several alternatives exist for key steps of the
measurement process such as sample preparation, soft ionization and the choice
of mass spectrometer. Nonetheless, it is fair to say that the analysis of complex
protein mixtures mainly follows a generic ‚shotgun‘ workflow that is discussed in
the following section and depicted schematically in figure 1. The workflow of the
MALDI-TOF mass spectrometer that is used in clinical microbiology nowadays
diﬀers substantially from the generic ‚shotgun‘ workflow, because the require-
ments in terms of costs, eﬃciency, handling and depth of proteomic coverage are
diﬀerent. Its characteristics will therefore be briefly described separately in the
next subsection.
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Figure 1: Generic shotgun proteomics workflow. A: Sample preparation: The isolated
proteins are digested with site specific endoproteases and purified in stage tips. B: HPLC
tandem MS: Peptides are separated by HPLC and transferred to the vacuum of the mass
spectrometer via ESI. The top n m/z peaks in the full mass scan are isolated for fragmentation
with a quadrupole and the resulting MS/MS spectra are recorded. C: Protein identification
and quantification: The MS/MS and MS spectra together with sequence databases are used to
determine the identity and quantity of the proteins in the original sample. This is done with
sophisticated software environments like MaxQuant [11] that take multiple hypothesis testing
into account and limit the false discovery rate to a predefined threshold.
A major hurdle for the analysis of large biomolecules by means of MS was their
ionization and transfer into the vacuum of a mass analyzer. Franz Hillenkamp
and John Fenn developed two diﬀerent soft ionization methods in the 1980ies
that solved this problem, MALDI [12] and ESI [13].
In MALDI the analytes are placed on a solid organic matrix and get desorbed
by a laser beam pulse. As they detach from the matrix, the analytes or their
fragments accept protons that originate from the organic matrix. The resulting
ions are up to 200 kDa in weight and mainly singly charged.
In ESI ions are created by electrostatic dispersion and evaporation as the ana-
lytes enter the vacuum of the mass analyzer in small charged droplets of solvent.
This idea is realized by applying a voltage of several kilo Volts between the tip
of a glass capillary and the entrance funnel to the vacuum of the mass analyzer.
The principles of MALDI and ESI are depicted in figure 2. Since a high pressure
liquid chromatography (HPLC) can be directly coupled via ESI to a mass spec-
3
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Figure 2: Soft ionization methods for MS based proteomics. A: MALDI: The pulsed
laser beam desorbs the analytes that are embedded in the organic matrix. The energy depos-
ition of the laser pulse enables analytes and matrix components to separate from the matrix,
often in the form of singly charged ions. B: ESI: The application of a strong electric po-
tenial between the needle of an HPLC and the vacuum funnel of a mass spectrometer leads
to the formation of a cone beam with subsequent disintegration of the solute in small charged
particles. Due to the evaporation of solvent the droplets split into ever smaller droplets in
a process called Coulomb explosion resulting in charged analyte molecules in the gas phase.
Modified from [14].
trometer, ESI is today the most common soft ionization method. In ESI-MS,
the complexity of proteomics samples gets reduced by separating the probes ac-
cording to their hydrophobicity prior to the analysis in the mass spectrometer.
HPLC is a very powerful separation technique for peptides and MS-based pro-
teomics leverages improvements in chromatography for ever deeper proteomics
analyses. Consequently, the generic shotgun workflow relies on the coupling of a
HPLC via ESI to the mass spectrometer (fig. 1 B).
Although soft ionization methods allow the analysis of proteins as a whole, it
is easier and more eﬀective to digest complex protein mixtures with sequence-
specific endoproteases like Trypsin or LysC and measure the resulting so called
tryptic peptides (fig. 1 A). This approach is called ‚bottom-up‘ principle and
relies on subsequent bioinformatic reconstruction of the proteins in the sample
(fig. 1 C). The disadvantage of the bottom-up approach is that it includes addi-
tional sample preparation steps prior to the measurement resulting in additional
costs, sample loss and potential errors such as misscleavages of the endoproteases
used. In general, cell lysis, protein purification and protein digestion should be
performed carefully, because a good yield of tryptic peptides from the sample is
imperative for accurate proteomics [15].
Today two main types of mass analysers are common, time of flight instruments
(TOFs) and Orbitrap instruments - leaving the less common Fourier-transform
ion cyclotorn resonance analyzers and linear ion traps aside [16, 17]. Both Or-
bitraps and TOFs oﬀer high mass accuracy, m/z resolution, acquisition speed
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and dynamic range of protein abundance [18–21]. Mass accuracy denotes the
diﬀerence between measured mass and actual mass, m/z resolution describes
the capacity to separate two signals with only slightly diﬀerent m/z values. In
daily practice, the robustness of the instrument’s performance is also worthwhile
consideration and arguably Orbitrap analyzers owe part of their success to their
stable operating performance.
The Orbitrap analyzer consists of a spindle shaped electrode and an outer barrel
shaped electrode as depicted in figure 3 A. The ions to be measured are collected
in a C-trap prior to their eccentric injection into the space between the two
electrodes of the Orbitrap. As the ions enter the Orbitrap they oscillate at
diﬀerent frequencies along the axis depending on their m/z ratio and induce
currents in the outer electrode. A Fourier transformation of the detected signals
allows to calculate the m/z spectrum. The limited space in the C-trap and the
Orbitrap leads to space charging eﬀects if too many ions are accumulated - a
major disadvantage of this type of mass analyzer. Increasing the size of the
Orbitrap and the C-trap is not an option since longer Orbitraps decrease the
acquisition speed due to slower oscillation frequencies. Furthermore, the precise
injection of more ions from a larger C-trap is challenging. For these and other
reasons the potential for improvements of Orbitrap analyzers seem limited.
A BC-Trap
Orbitrap
analyzer
Ion package
Reflector
Detector
collision
cell
selection
quadrupole
ion source
Figure 3: Two common mass analyzers: A: In Orbitrap analyzers an ion package is injected
from a C-trap into the orbi cell. The frequency of the horizontal oscillation is used to calculate
the m/z ratio via a Fourier transformation. Adapted from [22]. B: In TOF instruments, the
ions are accelerated vertically into a field free drift tube. In many cases the ions get reflected
to double the flight path before they get detected on a microchannel detector plate.
TOF mass analyzers accelerate packages of ions orthogonally in an electric field
of known strength. This leads to a velocity dispersion of ions according to their
m/z ratio. The diﬀerence in velocity between diﬀerent ion species is subsequently
detected by measuring the time of flight of the ions for a defined distance (fig.
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3 B). TOF analysers operate at high scan speed and have the potential to reach
high sensitivity, accuracy and good signal to noise ratios. Improvements in the
guiding of ions along their trajectories and the sensitivity of the microchannel
detector plate would make TOF instruments even more attractive. Already now
TOF instruments represent a competitive alternative to Orbitrap analyzers for
proteomics [20, 23, 24]. Additionally, the coupling of an ion mobility trap with a
TOF instrument could render additional performance improvements which might
be relevant for medical diagnostics as discussed in the Appendix section C of this
thesis.
The mere recording of the m/z spectrum of the tryptic peptides is not suﬃcient to
accurately determine the peptide sequence in most cases. Therefore, most mass
spectrometers additionally isolate specific ions with a quadrupole and fragment
the selected ions in a collision cell. The m/z spectrum of the fragment ions -
the MS/MS spectrum - is in turn determined (fig. 1 B). Commonly, the ten
to twenty most abundant peptide species of a given MS spectrum are isolated
for fragmentation before the next MS spectrum is recorded - an approach called
data dependent acquisition.
The reconstruction of the proteins that were originally in the sample based on
the recorded MS and MS/MS spectra is a challenging endeavor. In the early
days of mass spectrometry based proteomics human experts had to examine
many MS/MS spectra to validate computationally calculated results. Nowadays,
sophisticated software oﬀers fast and highly accurate interpretation of mass spec-
tra with stringent statistical cut-oﬀs. The most popular platform is MaxQuant
[11] and the following description outlines its processing algorithm, although the
same steps are carried out by alternative platforms in more or less the same way
[25, 26].
The first step in the processing of the raw mass spectra is the feature detec-
tion. To this end, three dimensional hills above the m/z-retention time plane
are gathered. Fitting Gaussians to each peak in the MS spectrum and calculat-
ing the weighted average of the centroid masses of each feature increases mass
precision. The charge state of an ionized peptide can be calculated based on its
isotope pattern. Two chemically identical peptides can diﬀer in mass due to a
diﬀerent composition of isotopes and hence form so called isotopologues. These
isotopologues can be easily grouped since they diﬀer exactly in multiples of one
Dalton divided by the charge state of the peptide. The grouped isotope pattern
constitutes a feature of known charge state and m/z ratio.
In a second step the detected features are mapped to their peptides of origin.
Ideally, the MS/MS spectrum is so rich in fragments of diﬀerent length, that
the peptides sequence can be reconstructed entirely based on the fragment spec-
trum. In practice this is rarely the case. Hence, the features are compared to a
6
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list of candidate peptides that is created by in-silico digestion of proteins based
on the DNA sequence of the organism studied. In order to avoid false discov-
eries, a target-decoy approach is used to statistically control the false discovery
rate (FDR) [27, 28]. This means that an equal number of fake candidate pep-
tides is created artificially and added to the list of actual candidate peptides.
Subsequently a matching score for each peptide in the joint list of candidate
peptides is calculated and the peptides are ranked according to their matching
score. The peptides with the best matching scores are accepted as hits as long
as the total percentage of fake peptides among the accepted peptides does not
exceed a predefined threshold - usually 1%.
Assigning the identified peptides to proteins is not straightforward and has been
coined the ‚protein interference problem‘. Some peptides can be the products
of the tryptic digestion of diﬀerent proteins. In such a case, it is impossible to
reconstruct from which protein they actually originated. Instead, these peptides
are assigned to the entire group of proteins from which they could potentially
originate. Another diﬃculty arises by the size of the proteomics dataset that
requires to impose a FDR on the protein level in addition to the FDR on the
peptide level. This is done by ranking the identified proteins or protein groups
based on a score calculated from the posterior error probabilities of the peptides
and applying the target decoy approach once again. The aforementioned drafts
of the human proteome did not apply a FDR on the protein level which is why
the reported results should be treated with caution [8, 9].
The mere identification of proteins is not suﬃcient to address most biological
questions, but quantitative readouts are desired. Hence, sophisticated quanti-
fication methods have been developed for mass spectrometry based proteomics.
The problem is that diﬀerent peptides do not result in MS signals that are directly
proportional to their original amount in the sample, since they diﬀer in chemical
behavior. For example, the ionization eﬃciency varies largely along the liquid
chromatography (LC) gradient and for peptides with diﬀerent physicochemical
properties [29].
There are several ways to circumvent this bias. One of the most accurate quanti-
fication strategies is stable isotope labeling by amino acids in cell culture (SILAC)
[30]. In SILAC two cell culture populations - i.e. treatment and control - are
grown on diﬀerent media. The medium of one cell culture only contains 12C
labeled arginine and the medium of the other cell culture only contains arginine
labeled with 13C. Hence, the resulting peptides of the two samples after diges-
tion with trypsin are isotopologues with a mass diﬀerence of 1Da. Consequently,
their chemical behavior is identical, in particular their ionization eﬃciencies. As
a consequence, the resulting ratio of the mass intensities of these isotopologues
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reflect the ratio of their original protein ratios between the two samples. How-
ever, metabolic isotope labelling can be expensive and is impractical for in vivo
experiments not to mention experiments in humans. As an alternative the la-
belling can be performed during sample preparation with chemical labels such
as di-methyl labeling [31], isobaric Tags for Relative and Absolute Quantitation
(iTRAQ) [32] or tandem mass tags (TMT) [33].
Chemical labeling reagents also allow multiplexing of samples by attaching dif-
ferent labels to diﬀerent samples [34]. Using TMT reagents 10 samples have
already been analyzed in parallel [35] and TMT 18-plex is under development
[36]. This could be of great value for the application of proteomics in medical
diagnostics, because it greatly reduces measurement time per sample. For the
applicability of TMT reagents in medical diagnostics challenges in the reagent’s
stability and the labeling eﬃciency still need to be overcome.
Another very popular quantification strategy is label free quantification (LFQ).
This approach assumes that the peptides of a protein that are most readily detec-
ted have nearly the same ionization eﬃciency. Using these peptide intensities for
quantification of the respective proteins and normalization of the signals yields
accurate results for protein quantification [37]. Not surprisingly, quantification
is more accurate for proteins with high abundance, but fold changes can still
be reasonably detected across several orders of magnitude [37]. The beauty of
LFQ is that it can be applied to any proteomics sample without any additional
preparation steps. This renders the combination of multiplexing samples with
TMT reagent and quantifying them with LFQ algorithms particularly attractive
for applications of proteomics in medical diagnostics.
1.3 MALDI-TOF in clinical microbiology
The MALDI-TOF mass spectrometers that are now used for routine clinical dia-
gnostics diﬀer in several aspects from the generic ‚shotgun‘ workflow explained
in the last subsection. The food and drug agency approved the first mass spec-
trometry system for automated identification of pathogenic bacteria and yeasts
in 2013. This was the result of a long development process that started in 1975,
when Anhalt and Fenselau first proposed to identify bacteria by mass spectro-
metry [38]. Twenty years later, several groups managed to diﬀerentiate selected
microorganisms by MALDI-TOF MS from intact bacterial cells [39, 40]. How-
ever, it was only a couple of years ago that scientists managed to reproducibly
identify a wide range of clinically relevant bacteria with reasonable accuracy
[41, 42].
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Figure 4: Application of MS in clinical microbiology: Bacterial colonies from agar plates,
blood cultures or urine samples are transferred to MALDI-TOF mass spectrometers. The
resulting mass spectrum is compared to datasets of previously characterized microorganisms
to identify the bacterium or yeast under study. Since mass spectrometers can also measure
metabolites or oligonucleotides, they allow to determine certain bacterial resistances via the
detection of hydrolysis products or to identify bacteria with ESI-quadrupole-TOF MS following
PCR amplification. Adapted from [43].
The basic workflow of MALDI-TOF MS is graphically summarized in figure 4.
The first step in the discrimination of bacteria or yeasts with MALDI-TOF MS
is to grow the microorganism on a culture plate or a broth culture [44]. For urine
samples, it has been shown, that bacteria can be directly identified from samples
with bacterial concentrations as low as 103 colony forming units per ml [45, 46].
The bacterial colonies are either directly transferred to the MALDI target plate
together with strong organic acid and the matrix solution or incubated with
ethanol, formic acid and acetonitrile for protein extraction prior to the transfer.
These additional sample preparation steps oﬀer enhanced biomarker detection
and result in higher spectral scores [47]. Subsequently, the mass spectrum of the
microorganism is recorded by means of MALDI-TOF.
The used TOF mass spectrometers commonly only record MS spectra, because
they lack a quadrupole and a collision cell to select ions for fragmentation. Many
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of the mass peaks originate from proteins of ribosomal origin that are particu-
larly useful to discriminate bacteria phylogenetically - a principle also used by
16S-RNA sequencing. The resulting mass spectra are then used to identify the
microorganism by comparing the spectrum to a library of mass spectra from mi-
croorganism. A score is calculated that expresses the certainty of identification.
Note that proteins and their quantities are not determined in this way, but the
direct comparison of mass spectra serves to identify bacteria or yeasts. This
also implies that non proteinaceous molecules such as metabolites or oligonuc-
leotides may play a part in the identification process. This can be used to detect
antibiotic hydrolysis products and hence verify antibiotic resistance [48].
Furthermore, in an alternative method called PCR-ESI-quadrupole-TOF MS,
the bacterial DNA can also be amplified using PCR followed by ESI and meas-
urement of the PCR products in a quadrupole TOF (QTOF) mass spectrometer
[49]. However, this alternative requires a diﬀerent type of mass spectrometer and
has not managed to establish itself in routine clinical microbiology.
1.4 Scope of the project
MALDI-TOF has fundamentally changed the way we identify bacteria in clinical
microbiology and challenged well established diagnostic methods. Given that
more complex mass spectrometers enable scientists to accurately quantify the
protein inventory of a tissue or bodyfluid within hours [50] the question arises
whether this technology might be of significance for other areas of medical dia-
gnostics. The research lab of Professor Mann has a small subgroup working on
this question. I had the great privilege to join this subgroup on clinical pro-
teomics for a period of one and a half years. In this period I worked on three
projects, one focusing on the determination of the human saliva proteome and
the oral microbiome, one devoted to the fast quantification of the human plasma
proteome and one method development project that implemented a new opera-
tion mode on a trapped ion mobility mass spectrometer. The first of these three
projects is the subject of this thesis, because it was mainly conceived and carried
out by me under the close supervision of Professor Matthias Mann, Professor
Sören Schubert, Dr. Nils Kulak and Dr. Garwin Pichler.
Saliva was chosen, since it can be collected non-invasively and enables a particu-
larly deep coverage of the proteome compared to other bodyfluids. The presented
dataset represents the deepest body fluid proteome recorded to date and provides
an unprecedented insight into saliva homoeostasis. Furthermore, the oral cavity
harbors the microbiome rendering saliva as an ideal medium to explore the cap-
abilities of mass spectrometry based proteomics for the direct characterization
of complex bacterial environments without prior culturing. Special emphasis
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was put on the simultaneous characterization of the oral microbiome by means
of proteomics, because it opens up new possibilities to study host pathogen in-
teractions and poses an alternative to the established sequencing approaches to
characterize the microbiome. The main results of this project were published in
Genome Medicine [51].
My contribution to this project included the conception together with Professor
Matthias Mann, the design and the performance of the majority of experiments
with the exception of the MALDI-TOF measurements and the plasma proteome
measurements that were designed and carried out by Dr. Jette Jung, Professor
Sören Schubert and Philipp Geyer respectively. Furthermore, I performed most
of the data analysis, receiving support from Dr. Pavel Sinitcyn and Professor
Jürgen Cox for the processing and interpretation of next generation sequencing
data. The MaxQuant software [11] that I used for the data analysis was written
by Professor Jürgen Cox.
The aforementioned plasma project was mainly conducted by Philipp Geyer.
Besides many discussions about the clinical focus of the project with Philipp, I
carried out several MS-based proteomics measurements of patient plasma. The
project demonstrates how plasma proteomics allows to study pathophysiological
changes systematically in an unbiased way and key results are presented in the
Appendix. The plasma proteomes of 43 obese individuals undergoing an acute
weight reduction therapy were determined across seven measurement time points
spread over more than one year. The quantification of more than 400 proteins
per sample gives a detailed, time resolved account of how lipoproteins and in-
flammatory factors respond to sustained weight loss. This study was published
in molecular systems biology [52] and serves as a blueprint for how plasma proteo-
mics can be exploited to discover new biomarkers or to examine the systematic
eﬀects of diseases.
The final project was technical in nature and mainly carried out by Florian
Meier and Scarlett Beck. It dealt with the implementation of trapped ion mo-
bility spectrometry (TIMS) on a high end quadrupole TOF mass spectrometer.
While TIMS has been coupled to less complex mass analyzers in the past, this
instrument type is in the middle of development and could lead to substantial
improvements in instrument performance. Specifically, the so called Parallel
Accumulation-Serial Fragmentation (PASEF) operation mode has the potential
to drastically increase sequencing speed and sensitivity thus enhancing through-
put.
I was actively involved in the design of the PASEF operation mode and conduc-
ted preliminary experiments on the prototype together with Florian Meier and
Scarlett Beck. Part of the results of this project were published in the Journal
of proteome research [53]. Since TIMS can also be realized in a MALDI-TOF
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setting the development could eventually also impact the microbiological use of
MS that is already in place. Either way, PASEF brings technological advances
about that have the potential to make MS based proteomics way more compet-
itive for a wide range of applications in clinical diagnostics. Key findings of this
project will be briefly discussed in the Appendix.
1.5 Body fluid proteomics
Fast and comprehensive laboratory diagnostics has become one of the corner-
stones of modern high performance medicine. The measurement of hallmark
biomarkers from body fluids is a valuable piece of information to make a dia-
gnosis, monitor drug therapy or to determine organ function. The vast majority
of these biomarkers are proteins floating in the blood. Medical doctors commonly
focus on a small subset of proteins that are known to have altered concentra-
tions in the blood in certain diseases. Out of these, they select those with highest
sensitivity and specificity for the hypothetical disease and measure them mostly
with Enzyme-linked Immunosorbent Assays (ELISA) - the workhorse of protein
analysis in clinical chemistry.
Proteomics would allow to assess the pathophysiological changes in a disease
on the systems level. Instead of delivering the changes of a handful of known
biomarkers, it can uncover the alterations of all the major proteins in body
fluids such as blood, saliva or urine. This much more detailed picture of the
health state of an individual would enable doctors to confirm a diagnosis by
assessing a panel of several hundreds or thousands of proteins. While many
of the measured proteins are likely to have a low sensitivity and specificity for
diagnosing the disease in question, a score calculated on the basis of multiple,
potentially hundreds of protein biomarkers is likely to yield high sensitivity and
specificity. Furthermore, the determination of a patient’s body fluid proteome
could reveal unexpected pathological alterations that were not suspected from the
patient’s symptoms. Certainly, correction measures preventing the accumulation
of false positives in such a diagnostic test would need to be put in place. The
calculation of disease scores could again turn out to be helpful for the prevention
of false positives.
Another advantage of body fluid proteomics is that it would allow to eﬃciently
determine individual reference ranges for thousands of protein concentrations in
the body of an individual. As discussed in the project on the plasma proteome
in the Appendix B, the interindividual variation of plasma protein levels are
notably higher than the intraindividual variation of plasma protein levels in a
longitudinal study. Individual reference ranges would allow doctors to notice
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deviations from healthy homoeostasis earlier. Therefore, proteomics could be of
great interest for personalized medicine in the future.
Despite the appeal of this approach, its advantages have been precluded by
the diﬃculty to quantify thousands of proteins in a body fluid accurately in a
reasonable measurement time. This is mainly due to the dynamic range problem
of proteomics, namely the simultaneous presence of proteins with low abundance
and high abundance in the same sample. This makes it exceedingly diﬃcult to
measure low abundant proteins and to characterize samples with huge dynamic
range down to the least abundant protein species. Over the last years, Professor
Mann’s laboratory has spent considerable eﬀort on streamlining and simplifying
its proteomics platform in order to enable its clinical application. The project
on the dynamics of the saliva proteome [51] and the project on the changes of
the plasma proteome [54] during weight loss intend to demonstrate the utility of
proteomics for medical diagnostics.
1.6 The human saliva proteome
The oral cavity has a highly complex homoeostasis that is maintained by saliva.
Saliva’s functions include pre digestion, the lubrication of ingested food and bac-
terial defense. Disruptions in saliva secretion can therefore result in pathological
conditions such as tooth decay, gingivitis or pharyngitis. Saliva is mainly secreted
by the three pairs of salivary glands, but also contains shed epithelial cells and
a multitude of microbes.
The Human Microbiome Project (HMP) has revealed that the oral microbi-
ome and the gut microbiome are the most diverse in the human body and that
the two are highly correlated [65]. Increasing evidence suggests a link between
the human microbiome and diseases like obesity, allergies or multiple sclerosis
[66–69]. This created enormous interest in the human microbiome and its in-
teraction with the human body. With respect to the oral microbiome, it is well
established that tooth decay and gingivitis are not caused by a single bacterial
species, but by several species acting together [70]. The interest in saliva and
its protein composition has been driven by these findings recently and promising
steps towards the characterization of the human saliva proteome have already
been undertaken [71, 72]. Yet, the authors either used extensive fractionation of
their samples hence sacrificing quantitative accuracy and throughput or relied on
ELISA based analyses that implied only a coverage of a few hundred proteins.
The analysis of the oral microbiome has so far relied on sequencing approaches
or classical microbiology. Culture based analyses of complex microbiomes come
at the disadvantage of having to grow the respective organisms outside their
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natural environment in single colonies. While some bacteria might not even
grow on agar plates, many of them will adapt to the culture conditions hence
concealing their in vivo characteristics. On the contrary, sequencing approaches
allow to analyze the collected sample with minimal delay at great sensitivity
and therefore represent the method of choice for the analysis of highly complex
microbiome studies. Yet, the bacterial genomes only help to identify bacteria,
but reveal little about their state of being. MS based proteomics opens up the
possibility to investigate the microbiome on the basis of its protein constituents
and yields information about the host’s interaction with his flora at the same
time. This approach could also be of interest for bacterial biotypization in the
clinic, because it could be faster than culture based assays. Given the success
of MALDI-TOF and the fact that the speed of analysis is mainly limited by the
growth of the colony in this technology, assays that do not require cultivation
seem to be the next logical step. Since there have been hardly any attempts to
characterize the oral microbiome by MS based proteomics, the saliva project also
aimed to investigate whether in depth MS based proteomics can capture the oral
microbiome.
Here we present the quantitative saliva proteomes of eight healthy individuals
with unprecedented depth of more than 5500 proteins. In addition, we developed
a single-run workflow that requires minimal amount of human saliva and delivers
the quantities of thousands of proteins within four hours. This allowed us to
investigate dynamic changes and inter-individual diﬀerences of the human saliva
proteome. We also addressed the long-standing question as to which degree the
quantities of proteins in saliva and plasma are correlated. Our measurements also
quantified more than 2000 microbial proteins from 50 diﬀerent bacterial genera.
We co-analyzed these proteomics results with next-generation sequencing data
from the HMP and compared them to MALDI-TOF mass spectrometry from
microbial cultures and found strong agreement in both cases. Finally, we could
show that the oral microbiome undergoes substantial changes upon eating and
tooth brushing and diﬀers between individuals.
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The application of mass spectrometry based proteomics to identify bacterial spe-
cies has largely been limited to MALDI-TOF technology. Consequently, com-
munity standards and manufacturer’s recommendations as to how to identify
bacterial samples by mass spectrometry only exist for the routine clinical ana-
lysis of bacterial cultures with MALDI-TOF mass spectrometry. The use of
ESI-MS based shotgun proteomics for the identification and quantification of
bacterial communities therefore represented a challenge and the methodology
presented here could not rely on established protocols. Instead, the choice of
sample preparation, protein database and bacterial quantification represent the
Mann lab’s experience of how the new questions that arise from the analysis of
bacterial samples, can be best addressed. The rational for choosing the following
methodology is mainly outlined in the results section below. However, it should
be noted, that the chosen methods are likely to be subject to refinement as the
use of ESI-MS based shotgun proteomics becomes more widely adopted for the
study of microbial communities.
2.1 Study cohort
We collected saliva from four female and four male, healthy, non-smoking donors
aged 24 to 40 years with Caucasian backgrounds. All individuals did not take
any drugs or antiseptics, regularly visited the dentist, showed no permanent
medical condition and no signs of active inflammation, infection or bleeding. All
donors provided their written informed consent to participate in this study and
to publish the acquired results. The study was approved by the ethics committee
of the Max Planck Society. All subjects donated two saliva samples at diﬀerent
timepoints, once at around 7 a.m. immediately after waking, before drinking,
eating or tooth brushing and once at around 10 a.m. after the donors had eaten
breakfast and brushed their teeth.
We also collected three samples immediately after one another form one donor at
10 a.m., prepared them in parallel and compared the results from this workflow
replicate. We found a high reproducibility of R2=0.92, consistent with previous
bodyfluid analyses on our measurement platform [54]. The high reproducibility
of our workflow encouraged us to refrain from replicates and use the available
measurement time for the analysis of several donors and timepoints instead.
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2.2 Sample collection and preparation
All donors abstained from eating and drinking at least 30 minutes prior to
the collections. Saliva was collected with sterile cotton swabs that were sub-
sequently placed in Eppendorf tubes containing 200µl of lysis buﬀer (1% so-
dium dodecyl carbonate (v/v), 10mM tris (2-carboxyethyl) phosphine, 40mM
2-chloroacetamide, 100mM Tris buﬀer pH 8.5). The swabs were thoroughly
squeezed at the inner wall of the Eppendorf tube prior to removal. More than
100µg of protein as estimated by the Bradford protein assay were reproducibly
obtained in this way for the ensuing sample preparation with our in-StageTip
protocol [15]. To this end, 20µg of protein were digested by 0.4µg trypsin and
LysC in our lysis buﬀer at 37  C shaking for 60 minutes. Subsequently, we ad-
ded trifluoroacetic acid until a 1% concentration was reached. 20µg of acidified
peptides were placed on a styrenedivinylbenzene-reversed phase sulfonate (SDB-
RPS) StageTip [55]. The peptides bound to the SDB-RPS matrix and were
purified by washing them with 200µl of water. They were finally eluted with
60µl 80% acetonitrile (v/v) and 1%ammonium (v/v). The resulting mixture
was dried in a SpeedVac concentrator at 45  C, and resuspended in A* buﬀer
(2% acetonitrile (v/v), 0.1% trifluoroacetic acid (v/v), pH 2) to a concentration
of 1 g/l.
For our deep human saliva proteomes, 15µg of each sample were fractionated
in an 80-min basic reversed phase gradient on a 20-cm, 75µm thick column
that was in-house packed with ReproSil-Pur C18 beads (Dr. Maisch GmbH,
Germany). A fraction lasted 3 minutes of the gradient and the resulting fractions
were concatenated to form eight final fractions per sample. These concatenated
samples were again dried in a SpeedVac concentrator at 45  C, and resuspended
in A* buﬀer (2% acetonitrile (v/v), 0.1% trifluoroacetic acid (v/v), pH 2) to a
concentration of 1 g/l.
The fractionated samples as well as the single run samples were separated with
a 100-min chromatography gradient using an ESY-nLC 1000 ultra-high pressure
system (Thermo Fisher Scientific) and a 40-cm column as above. The column
was heated to 50   C by an in house designed conductive oven to enable high
flow without pressures exceeding 1000 bar. By applying a 2.2 kV potential dif-
ference, the column was on line coupled to a Q Exactive HF mass spectrometer
(Thermo Fisher Scientific). The column tip faced the entrance funnel of the mass
spectrometer at an angle of 30   with the horizontal plane.
The MS scan range was from 300 to 1650 m/z with a resolution of 120,000 at
200 m/z and a maximum injection time of 55ms. We applied a top 15 MS/MS
method using higher-energy collisional dissociation with a quadruple isolation
width of 1.5 m/s and a dynamic exclusion time of 30 s, meaning, that a given m/z
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peak was excluded from isolation for the 30 s after being targeted for isolation.
These settings of mass range, injection times, resolution, isolation width and
dynamic exclusion have been shown to yield optimal results in this type of mass
spectrometer for complex proteomics samples [19].
2.3 Protein database
We used the human reference proteome from Uniprot for our human only analysis
(downloaded on 24 June 2015 from http://www.uniprot.org/). For the bacterial
analysis, the Uniprot fasta files of all named species of the Human Oral Microbi-
ome Database [56] with more than five protein sequences were downloaded (on
24 June 2015 from http://www.uniprot.org/) and combined it with the human
reference proteome for the joint analysis.
In both databases, we only accepted Swiss-Prot reviewed entries, meaning, that
the respective protein entries were manually annotated and the records were
based on information from literature and curator-evaluated computational ana-
lysis rather than computationally analyzed data. Unreviewed databases tend to
be much bigger and result in less reliable protein identification or - if a FDR is not
imposed - in an accumulation of false positives. The human database comprised
90.5K sequences and the joint database consisted of 1209.4K entries.
2.4 Protein identification and quantification
We analyzed our proteomics raw data in MaxQuant (version (1.5.3.15)) [11].
This platform encompasses several algorithms for the statistically robust iden-
tification and quantification of peptides and proteins from high-resolution MS
data. It has established community standards for statistically sound protein
quantification and is now the most widely used computational platform in shot-
gun proteomics.
The integration of serial mass measurements and corrections of mass oﬀsets into
the calculation of peptide mass yield accuracies in the parts per billion range.
Internally, MaxQuant uses the Andromeda search engine [57] to match the de-
tected features against the reference proteome. A target decoy approach allows
to impose a FDR on both the peptide and the protein level to identify peptides
and proteins stringently. Furthermore, the MaxLFQ algorithm provides a highly
accurate quantification of label-free proteomics samples [37] - ideally suited for
our purpose.
Only tryptic peptides that were at least seven amino acids long and had two
missed cleavages at the maximum were considered by MaxQuant. 247 potential
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contaminants as listed by MaxQuant [11] were excluded from the analysis, result-
ing in a database of 0.64 million candidate peptides for the human database and
5.9 million peptides for the joint database, that fulfilled the criteria mentioned
above. Search parameters were set to the default setting of MaxQuant version
1.5.3.15. The mass tolerance was thus set to 4.5 parts per million at the MS
level and 0.5 Da at the MS/MS level, N-acetylation of proteins’ N-termini and
oxidation of methionine were accepted as variable modifications and carbamido-
methylation of cysteine as fixed modification. We used the MaxLFQ algorithm
for relative, label-free quantification with the minimum ratio count set to 1.
We analyzed the fractionated and single run measurements together in order
to exploit the match between runs function in MaxQuant [58]. This algorithm
optimizes peptide identification by aligning the elution times of diﬀerent runs
of the same tissue sample. Subsequently, precursors that are not selected for
fragmentation in one run can be identified from other runs, in which they are
selected for fragmentation. This way, even more peptides can be identified and
quantified in highly complex peptide mixtures. The search parameters for the
joint database were the same as for the human database except for the use of the
so called split by taxonomy id algorithm on the phylum level and the exclusive
use of unique peptides for protein quantification.
The split by taxonomy id algorithm is more thoroughly discussed in the results
section. Briefly, the analysis of samples consisting of several species poses a chal-
lenge, because some peptide sequences are potentially shared by organisms. As a
consequence, it is not possible to assign the peptide to one organism. Note, that
a similar problem arises, as a peptide sequence is shared by several proteins from
the same organism. This scenario however is resolved by MaxQuant by creating
a protein group that contains all proteins with the given peptide sequence.
For the purposes of this work, the creation of protein groups containing human
and bacterial proteins does not pose a viable solution. First, shared peptides
could lead to the identification of proteins from other species, simply because
peptides from other species shared peptide sequences with the respective protein.
This is particularly relevant, if the protein abundances between human proteins
and bacterial proteins is great. Figure 9 B demonstrates, that the abundance
of bacterial proteins is substantially smaller than the abundance of most human
proteins. Second, this abundance diﬀerence could lead to substantial quantific-
ation distortions, if peptides were not carefully attributed to their organism of
origin.
Our analysis of the sequence identity among bacterial and human peptide se-
quences considered by MaxQuant in figure 9 A demonstrates, that the overlap is
rather small, amounting to just 0.04%. This provides evidence, that the poten-
tial distortions from shared peptide sequences is limited. Yet, we cannot assume
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that the probability of MS peptide identification is equally distributed across
the peptide sequence space. Given that the shared sequences are likely to belong
to conserved genomic regions encoding essential proteins, these sequences are
potentially overrepresented among the identified peptides.
Therefore, we decided to allow the formation of protein groups on the phylum
level only, hence preventing a false assignment from human to bacteria or bacteria
to human. Shared peptides were simply excluded from analysis. Along these
lines, we only used unique peptides for the quantification of proteins, meaning
that only peptides that were unique to a protein were used to estimate the
respective protein abundance. This way, an overestimation of a low abundant
protein through a shared peptide with a high abundant protein is prevented.
Together, the split by taxonomy id and the quantification with unique proteins
provide a robust methodology to analyze multi-organism protein data also for
future investigations.
2.5 Data analysis
MaxQuant output tables were further analyzed in Perseus (version 1.5.2.12) [59]
- program that is tailored for the biological downstream analysis of highly mul-
tivariate quantitative protein abundance data. All proteins from the decoy data-
base as well as proteins only identified by site and all contaminants were removed
- including all keratin type I and II proteins. On the one hand, keratin type I
and II are certainly expected in saliva due to shedding of epithelial cells, but
on the other hand it is highly likely, that the samples are contaminated with
keratins from the skin during sample preparation. The quantity of keratins in
saliva would therefore be highly overestimated and we decided to exclude them
from the analysis altogether.
All quantified proteins were ranked according to the mean LFQ intensities of
the fractionated waking and postprandial samples of all donors. The means of
low abundant proteins, that were not quantified in all donors were calculated
by taking the LFQ mean among the donors in which the protein was quantified.
Proteins were annotated with Gene Ontology terms and Uniprot keywords and
a one-dimensional annotation enrichment analysis of these terms was calculated
[60]. To correct for multiple hypothesis testing a Benjamini-Hochberg FDR of
2% was imposed.
The comparison of the human plasma and saliva proteome was achieved by trip-
licate plasma proteome measurements with a 45-min HPLC gradient of two of
our saliva donors. The sample preparation and MS measurement of the respect-
ive plasma samples was identical to that in Geyer et al. [54]. The resulting six
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raw files were analyzed together with the corresponding saliva raw files with the
MaxQuant settings described above.
Principle component analysis (PCA) was calculated on the logarithmized LFQ
intensities of all 16 single shot saliva measurements. The comparison of the
waking and the postprandial proteomes was done by filtering for 100% valid
values in all 16 samples and using a two sided t-test with a Benjamini-Hochberg
FDR of 5%and the s0 parameter set to 0.1. The significance analysis for the
upregulated proteins at the two timepoints was done by calculating a Fisher
exact test with 2% permutation based FDR.
The taxonomic tree in figure 8 was created by assigning peptides to bacteria.
The number of peptides that we were able to assign to the respective level of
this taxonomic tree was then written above the edges of this tree. Peptides that
were shared by certain genera were added to the number of the lowest taxonomy
edge shared by these genera (operating taxonomy unit). Genera that did not
have at least one unique peptide were excluded because we could not rule out
the possibility, that all the identified shared peptides attributed to this genus
originated other microorganism.
Since we found 1069 peptides from streptococci, we extended the tree for this
genus down to the species level. This was also partly motivated by Dr. Jung’s
remark, that the species diﬀerentiation of Streptococcus species can sometimes
be challenging with MALDI-TOF. Bacterial genus abundance was calculated by
summing the top ten peptide intensities for each genus in analogy to the top
three protein quantification method [61, 62] and neglecting genera with less than
ten peptides.
2.6 Comparison to sequencing data
For the comparison of our proteomics measurement of the oral microbiome to the
HMP genome sequencing data, we downloaded the protein multifasta file from
the HMP and analyzed fractionated and single run files with the MaxQuant
settings described above against the human reference proteome and the multi-
fasta file. The genomic quantification was performed by trimming the 764 fastq
files from the HMP in Trimmatic [63] and aligning the sequences using Burrows-
Wheeler alignment with default parameters [64]. The adapter, the leading and
trailing sequences with a Phred quality score below 10 were removed. Addition-
ally, reads with less than 36 nucleotides were not considered in the analysis.
Following Z-score scaling within each sample, a PCA of the reads per genus
of the whole genome sequencing dataset together with the top ten peptide in-
tensities per genus from the MaxQuant data was calculated. The body sites
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„saliva“, „tongue dorsum“, „attached keratinized gingiva“, „palatine tonsils“ and
„throat“ from the HMP were taken together in figure 9 D since they clustered
tightly in the PCA and are all connected to the oral cavity.
2.7 Comparison to MALDI-TOF mass spectrometry
For the MALDI-TOF MS analysis all donors collected saliva by passive drooling
into a sterile tube immediately after the 10 a.m. collection time point. 50µl of
each sample were instantly plated on one columbia, one chocolate blood agar
plate for aerobic bacteria and two Schaedler agar plates for anaerobic bacteria.
We incubated the anaerobic cultures under anaerobic conditions at 37  C for
at least five days and the aerobic cultures at 5.8% CO2 for 3 days. Diﬀerent
colonies were subcultured for MALDI-TOF MS identification as judged by visual
and morphological evaluation by trained microbiologists.
The colonies were analyzed in duplicates following the protocol recommended
by Bruker Daltonik. Briefly, a single colony was transferred onto the target
plate and covered by 1µl of matrix solution containing 10mg/ml of ↵-cyano-4-
hydroxy-cinnamic acid in 50% acetonitrile/2.5% trifluoroacetic acid (↵-HCCA
portioned matrix, Bruker Daltonik GmbH, Bremen, Germany). We used a Mi-
croflex LT benchtop instrument operated by felxControl 3.3 software (Bruker
Daltonik GmbH, Germany) in linear positive ion mode at 60Hz laser frequency
with a mass range of 2 to 20 kDa for our measurements. The acceleration voltage
was set to 20 kV, the IS2 voltage to 18.6 kV and the extraction delay time was
0.2ms. The spectra were matched with the Bruker Taxonomy database version
4.0.0.1.
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3.1 In depth quantification of the human saliva proteome
Four female and four male healthy individuals with European genetic background
volunteered to donate saliva. They were asked not to eat or drink for at least 30
minutes prior to the saliva collection to minimize disruption and contamination
of the oral cavity. For the collection, each donor wiped the vestibule of the oral
cavity, the teeth and the sublingual compartment with a sterile cotton swab
(fig. 5). The recently developed In-StageTip sample preparation protocol [15]
enabled us to perform repeated measurements with the approximately 200 µg of
total protein from each swab.
A key step to any proteomics measurement is a high quality sample preparation.
Ideally, the vast majority is retained during the purification, modification and
digestion steps and any systematic bias is kept to a minimum. Even the best LC-
MS measurement technology cannot compensate for any losses or contamination
during sample preparation.
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Figure 5: Workflow for in-depth quantification of the saliva proteome: (1) Saliva is
collected by wiping the oral cavity with a sterile cotton swab thoroughly. Next, the cotton
swab is placed in an eppendorf tube filled with lysis and denaturation buﬀer. (2) Proteins
are digested and purified following the In-StageTip protocoll [15]. (3) Purified peptides are
either measured directly in single shot measurments or fractionated with high pH reverse-
phase chromatography into 8 fractions for in depth measurements. (4) Peptides are separated
on a 100min HPLC gradient and sprayed into a Q Exactive mass spectrometer operating
with a top 20 tandem mass spectrometry method. (5) The resulting spectra are analyzed in
MaxQuant and the Perseus software environment. The duration of each step is indicated below
the respective panel. Adapted from [51].
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The In-StageTip sample preparation keeps the number of processing steps to a
minimum by performing cell lysis, protein solubilization, protein denaturation,
reduction, alkylation of cystein residues, enzymatic digestion and peptide puri-
fication in the single enclosed volume of a stage tip. This way, the peptide yield
and the quantitative accuracy is very high. After a quick protein digestion of
one hour with Trypsin and LysC, the peptides were purified and fractionated
into eight fractions by basic reversed-phase chromatography. We subsequently
measured all fractions with a 100min LC gradient on a Q Exactive HF mass
spectrometer, followed by data analysis in MaxQuant (fig. 5).
We found more than 54,000 sequence-unique peptides across our eight donors
and more than 5500 diﬀerent protein species in our search against the human
reference proteome from Uniprot (fig. 6 A).
For both cases, we applied a FDR of 1% to limit false positives due to multiple
hypothesis testing. Note, that if peptides are not attributable to a specific pro-
tein, but occur in several proteins, a protein group is formed and such a protein
group is only counted once in the 5500 proteins form above. A majority of 78%
of the detected proteins were identified in each of the eight saliva donors, 90%
in at least six donors. Only 1,3% of the detected proteins were unique to one
donor and we expect most of these proteins to be false positives given the FDR
of 1%. From this we conclude that our saliva retrieval and processing is robust
allowing to compare thousands of proteins across individuals. We identified 5213
human proteins for one individual donor in the eight fractions. To our knowledge
this constitutes the deepest body fluid proteome measured for an individual to
date.
A comparison to plasma and urine proteomics revealed the reason for this re-
markable protein coverage in saliva compared to other body fluids. The 15 most
abundant protein species in saliva only account for 32% of the total protein mass
(fig. 6 B). By comparison the top 15 proteins in plasma and urine make up more
than 90% or 58% respectively [54, 73]. Digestive proteins, proteins involved in
immune defense and proteins belonging to the oral epithelium are among the
most abundant saliva proteins (fig. 6 B).
To further investigate the abundance distribution of diﬀerent saliva proteins, we
plotted the LFQ intensities against the protein abundance rank for all quantified
proteins and performed a 1D annotation enrichment analysis in the Perseus soft-
ware environment using GO terms and Uniprot keywords (fig. 6 C) [60]. This
analysis reveals the location of proteins with certain functions in the abund-
ance scale. For example, proteins that scored in the upper quartile of this
range were disproportionately often annotated with the terms „antibacterial
humoral response“ and „defense response to bacterium“. The terms „extracel-
lular space“ and
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Figure 6: Deep human saliva proteomes of eight healthy donors: A: The ovals indicate
the number of saliva proteins that are shared by the respective number of donors. On the right
the numbers and percentage of proteins are given. B: Gene names of the 15 most abundant
saliva proteins, their coeﬃcients of variation (CVs) at waking (w) and postprandial (p), abund-
ances in percentage of the total proteome and cumulative protein abundance (cum. amount).
Proteins in blue are digestive proteins, proteins in green are involved in immune defense and
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with key salivary proteins in red. 1D annotation enrichment revealed that certain GO terms
and Uniprot keywords are significantly enriched in certain abundance regions. D: Scatter plot
of the LFQ intensities of proteins shared in the saliva and the plasma proteome. Adapted from
[51].
„extracellular exosome“ turned out to be enriched near the median of the dis-
tribution. The low abundant proteins had annotations typical for intracellular
proteins such as „cytoplasm“ and „mitochondrial translation“. The annotation
enrichment therefore helps to grasp the quantitative distribution of functional
proteins from a global perspective. Altogether, the protein abundance of saliva
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spans a dynamic range of roughly six orders of magnitude as judged by our
present measurement depth.
The question, whether saliva is suitable to measure plasma biomarkers by proxy,
has been subject of ongoing debates [74]. It would be very convenient, if some of
the information usually obtained from blood tests could also be acquired from
saliva. Saliva collection is non-invasive, economical and well tolerated by all sorts
of patients including children. There have been attempts to use saliva more ex-
tensively for medical diagnostics especially as surrogates for plasma markers.
To address this issue, we determined the plasma proteomes of two of our saliva
donors in triplicate measurements [54]. Since more than 50% of the quanti-
fied plasma proteins were also present in the saliva proteomes of the respective
donors, we were able to perform the most comprehensive comparison of protein
quantities between saliva and plasma to date. The correlation between the LFQ
intensities of the shared proteins is low (fig. 6 D). Across all replicates it never
exceeded R2=0.20. In addition, we analyzed specific saliva samples separately
from the opening of the duct of the parotid gland, the duct of the sublingual and
submandibular gland and from gingiva, but each of these samples showed equally
low correlation to the plasma proteome (additional fig. C.2). Hence, we conclude
that saliva cannot directly be used to infer plasma biomarker levels, because the
saliva proteome and the plasma proteome show little overall correlation despite
an extensive number of shared proteins. This does not exclude the possibility
that individual protein levels show a high correlation between saliva and plasma,
nor does it undermine the diagnostic potential of saliva in general.
All our saliva results are publicly available via the proteomeXchange repository
(http://www.proteomexchange.org, accession number PXD003028) and via the
user friendly MaxQB database [75]. This platform allows to browse our data-
base for certain proteins and reveals the LFQ intensity, the abundance rank
and further information for a protein of interest. For example, additional fig-
ure C.1 B shows the protein transcobalamin-1 in a protein abundance plot. It
is a known component of saliva stabilizing cobalamin and protecting it against
acidity of the stomach. It also serves in the transportation of cobalamin in the
bloodstream. Cobalamin deficiency is common in the Western world with an
estimated prevalence of 20% in individuals aged 60 or above [76]. Given its
clinical significance, its standard values in the blood have been determined in
dedicated studies [77, 78]. Our saliva measurements revealed transcobalamin
levels in saliva together with thousands of other proteins, hence demonstrating
the utility that proteomics could have for clinical chemistry.
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3.2 Dynamics of the saliva proteome
In the past, studies have examined the intraday changes of hormones such as
cortisol in saliva [79]. However, changes in the saliva proteome during the day
have not been studied systematically yet. In the following, we will present the
intraday changes of the saliva proteome by comparing two timepoints, once im-
mediately after waking before tooth brushing and one at 10 a.m. after breakfast
and tooth brushing. Since this implied multiple measurements, we came up with
a more rapid, but still suﬃciently deep way to determine the levels of thousands
of saliva proteins.
The peptide fractionation we used to obtain our deep saliva proteome comes
at the cost of prolonging measurement time by the number of fractions. The
throughput in modern clinical chemistry motivated us to speed up our measure-
ment and to recover as many proteins as possible from a single-run experiment.
To this end, we skipped the fractionation step and used the same 100 minute
HPLC gradient to determine the saliva proteome of our eight donors at two dif-
ferent time points, once immediately upon waking before tooth brushing and
once after breakfast and tooth brushing. Despite the shorter total workflow time
of only 4 hours from collection to quantitative results we were able to identify
3835 proteins on average. The vast majority of 94% of these proteins were also
quantifiable using LFQ (additional fig. C.3 A). Repeated, simultaneous saliva
collection from the same individual followed by independent processing yielded
highly reproducible results with a mean coeﬃcient of determination R2 of 0.92
(additional fig. C.3 B). The interindividual diﬀerences were higher with a mean
R2 of 0.89. The CVs of protein LFQ intensities for the biological replicates
did not dependent on protein abundance (additional fig. C.3 C). Consequently,
our single-run workflow is suitable to reveal biological diﬀerences across a wide
abundance range.
We started our analysis of dynamic changes of the saliva proteome by performing
a PCA on our 16 single-run measurements. The PCA revealed that component
1 weakly separates the samples by sex, whereas component 2 separates the two
collection timepoints - waking versus postprandial after tooth brushing (fig. 7
A and figure C.4 A in the appendix). Hence sex and timepoint account for the
majority of variance in the data. To identify the proteins that drive this separ-
ation, we filtered for 100% valid LFQ values and plotted Benjamini-Hochberg-
corrected p-values versus fold change (fig. 7 B). That means, we only considered
proteins that were quantified in all 16 measurements and used the appropriate
correction for multiple hypothesis testing for this kind of analysis. Interestingly,
the proteins that were more abundant at waking were significantly enriched in
the keywords „antimicrobial“ (p= 6.6 · 10 8, enrichment factor (EF)=24) and
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„antibiotic“ (p= 6.6·10 8, EF=24). By contrast, the terms „thiol protease inhib-
itor“ and „secreted“ were significantly more abundant in the postprandial saliva
collection (p= 3.3 · 10 5, EF=42 and p= 8.7 · 10 9, EF=6, respectively). This
suggests that the protein composition of saliva at night is specialized on bacterial
defense while secretory digestive proteins dominate at 10 a.m.. As expected the
highly abundant digestive enzyme ↵ amylase had constantly higher quantities
after breakfast. Hence, body fluid proteomics is now able to accurately capture
shifts in protein abundance during the day.
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3.3 Identification of the oral microbiome by proteomic means
The large number of identified saliva proteins encouraged us to look for bacterial
protein signatures in our samples. We decided to include the Uniprot protein
sequences of all named bacterial species from the Human Oral Microbiome Data-
base that determined the oral microbiome by means of 16S rRNA sequencing [56].
The addition of these bacterial protein sequences to the human reference pro-
teome resulted in a search-space that was eleven times larger than the human
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database alone. By limiting the FDR to 1% the increased search space does not
lead to more falsely identified proteins, which is the case if no protein FDR is
applied.
The combined search space brings about the challenge to correctly assign pep-
tides to bacterial phyla since certain peptide sequences occur in proteins from
diﬀerent phyla. Closely related bacteria indisputably share many peptide se-
quences in common, but even not so closely related bacteria share many se-
quences [80, 81]. There is no community standard how to deal with this issue,
since our work is the first that aims to quantify the proteins of a human mi-
crobiome accurately and stringently with MS-based proteomics. We therefore
had to think of a way to reasonably assign shared peptides of closely related
organisms to proteins. We used the so called split by taxonomy id algorithm
on the phylum level in MaxQuant to deal with this issue. This algorithm was
originally developed by Professor Jürgen Cox to analyze xenografts of human
tumors transplanted to mice. We argue that it can also be used to accurately
quantify bacterial proteins in complex microbiological samples in the following
way.
Usually, a peptide shared between two proteins leads to the formation of a protein
group. Split by taxonomy id prevents this from happening for proteins from
diﬀerent phyla and hence neglects these peptides for protein identification. In
combination with the exclusive use of unique peptides for protein quantification
peptides shared by diﬀerent phyla do not contribute to the identification or
quantification of proteins (compare materials and methods). While we decided
to apply the split by taxonomy id algorithm at the phylum level of the taxonomy
tree this is by no means canonical. If the cut-oﬀ for the formation of protein
groups across diﬀerent species was applied on a lower level of the taxonomy
tree a large proportion of peptides would get neglected. However, if no cut-oﬀ
was applied at all, peptides from one phylum could contribute to proteins from
another phylum distorting its identification and quantification.
The issue and our rational for applying the split by taxonomy id algorithm on
the phylum level is visualized in figure 8. We placed the number of shared
bacterial peptides in our deep saliva proteomes on the respective branches of the
taxonomic tree. The peptides on each branch originate from protein sequences
that are shared by all bacteria down this branch and cannot be ascribed to one
microorganism in particular. Genera that did not have at least one peptide that
was unique to them were excluded. We hold that this is the best quantification
strategy for this kind of proteomics analysis at the present measurement depth.
In addition, we considered the possibility that the simultaneous presence of hu-
man and bacterial proteins in the oral cavity impairs our described human protein
quantification. To address this issue, we digested all bacterial protein sequences
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and all human protein sequences in our database in silico and identified the nonre-
dundant tryptic peptides that were long enough to be considered by MaxQuant.
Among these, only 0.043% originated from both bacterial and human protein se-
quences (fig. 9 A). Consequently, the presence of bacterial proteins in our saliva
samples does not substantially influence the quantification of human proteins.
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Along these lines we also wondered whether ingested proteins from food might
lead to a misquantification of human or bacterial proteins. We therefore per-
formed an analogous analysis for the protein sequences of wheat and bovine as
representative parts of a Western breakfast diet. The resulting overlap with bac-
terial or human peptides with at least seven amino acids in length was in each
case far below 1%, except for the overlap between human and bovine peptide se-
quences which amounted to 20.7% (fig. 10). Hence, our in silico analysis does not
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exclude the possibility of a quantification bias due to ingested bovine proteins.
However, we did not find a substantial diﬀerence in the quantity of human milk
or human muscle proteins between the waking and the postprandial samples, as
we would expect if a bovine diet had an influence on the quantification of human
proteins (compare fig.7).
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We concluded from these considerations that our approach of combining human
protein sequences with the protein sequences of the oral microbiome in a joint
database is suitable for the simultaneous analysis of human and bacterial pro-
teins. We were surprised that we identified 2234 diﬀerent bacterial proteins in
this way using our standard 1% FDR at the peptide and protein level. These
proteins originated from 50 diﬀerent bacterial genera from nine diﬀerent phyla.
This corresponds to almost 50% of the named genera in the Human Oral Micro-
biome Database with annotated UniProt proteomes. The number of identified
peptides diﬀered substantially between diﬀerent genera, ranging from only one to
1069 for streptococci. This allowed us to extend our analysis and to diﬀerentiate
twelve diﬀerent streptococcus species including Streptococcus mutans (fig. 8).
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We also employed MALDI-TOF MS of aerobic and anaerobic cultures of our
saliva samples according to standard protocols in clinical microbiology (compare
materials and methods). This complementary method found 14 diﬀerent genera
in total, all of which were also identified by shotgun proteomics. The number of
identified peptides of these genera suggests that they were comparatively abund-
ant in saliva (fig. 8). Certainly, the aim in clinical microbiology is not to identify
all bacterial species present in a sample, but rather to determine a dominant
pathogen eﬃciently and at low costs. Nonetheless, it is striking that unbiased
and relatively straightforward shotgun proteomics allows to identify such a high
number of bacterial genera without the need for cultivation.
3.4 Quantification of the oral metaproteome
Although bacterial proteins accounted for almost 35% of the total set of 6000
proteins in the analysis of the joint database, their total protein mass is rather
low. This is best illustrated by plotting the cumulative percentage of bacterial
proteins as a function of protein abundance rank (fig. 11). For example, the
percentage of bacterial proteins among the most abundant 1000 proteins was
only 5%. The proportion of bacterial proteins per 100 identified proteins con-
sequently rises steadily and reaches around 50% towards the limit of detection.
This suggest that as the depth of proteomic coverage improves, further bacterial
proteins will be revealed. This seems attractive, since a better coverage of the
bacterial proteome would allow to analyze how bacterial abundance and meta-
bolic pathways change across diﬀerent conditions.
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Figure 11: Distribution of bacterial proteins across the protein abundance range:
A: Percentage of bacterial proteins as a function of protein abundance rank. B: Percentage of
bacterial proteins per bin of 100 proteins. Adapted from [51].
Another abundance comparison between bacterial and human salivary proteins is
illustrated in the abundance rank plot in figure 9 B. Surprisingly, the most abund-
ant bacterial protein, F1WNZ3, the Moraxella catarrhalis homolog of chaperone
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protein HscA, was around 100 fold less abundant than ↵-amylase 1, the most
prevalent human protein. Other highly abundant bacterial proteins carry out
household functions like A0A096BHY1, a glyceraldehyde-3-phosphate dehydro-
genase, or E0Q9Q6, a subunit of DNA polymerase III. Their high abundance is
probably in part explained by the high degree of sequence identity across diﬀer-
ent bacterial species. Hence, their dominance could be explained by the joint
contribution of several diﬀerent genera.
Next, we wanted to come up with a method to estimate bacterial abundance
by our proteomics data. The majority of bacterial proteins belonged to one of
the four phyla, firmicutes, actinobacteria, bacteroides, proteobacteria, with 300
to 800 uniquely assigned proteins each (C.4 in the appendix). Yet, the number
of identified proteins is merely a very rough indicator of bacterial abundance.
Instead, we summed the MS intensity of the top ten most abundant peptides of
a microorganism across all samples in analogy to the top-three-peptide that is
well established for the label-free quantification of protein abundance [61, 62].
Microorganisms with less than ten peptides were excluded from our analysis.
Summing the intensities of all peptides of a microorganism would most likely
lead to an overestimation of abundance diﬀerences, just like the summation of
all peptide intensities of a protein causes an overestimation of protein abundance
diﬀerences.
We decided to consider all peptides of that microorganism for the determina-
tion of the ten peptides with highest intensity regardless of whether they were
shared with other microorganisms. This puts oral microbiota that share peptide
sequences with other oral microbiota at a slight advantage, but the alternative
of using only unique peptides would have put them at a great disadvantage. It
is important to note that this problem is inherent to any quantification method
of a diverse microbial community by means of MS-based proteomics. At the
present coverage of the proteome a sophisticated calibration of our quantifica-
tion method using a complementary quantification method seems impractical.
Still the described quantification method of bacterial genera by their top ten
peptide intensities should to be considered as rough approximations rather than
accurate quantifications.
The abundances of the top 20 bacterial genera in saliva as judged by the described
quantification are displayed in figure 9 C. Our results are in accordance with 16S
RNA studies of the human oral microbiome [82, 83] that found Streptcoccus and
Lactococcus as most abundant bacterial genera.
Another indication that our bacterial quantification measure roughly represents
actual bacterial abundances is our comparison to the quantitative results of the
HMP. We used the reads per genus of the HMP whole genome sequencing data-
base and processed them together with the genus abundance estimations from
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our MS data. The resulting PCA is displayed in figure 9 D and shows a close
co-localization of the two datasets. This is remarkable given the quantification
of bacteria used two completely diﬀerent methods and the samples originated
from diﬀerent donors. The similarity of the oral microbiome across individuals
is however well established [84].
The HMP analyzed the microbiome from diﬀerent parts of the body includ-
ing several separate sites in the oropharynx including saliva , tongue dorsum,
attached keratinized gingiva , palatine tonsils and throat. The sites in the oro-
pharynx all clustered together in the PCA thereby demonstrating that determ-
ining the oral microbiome from human saliva alone is a valid strategy.
3.5 Interindividual variation and dynamics of the oral microbiome
Our saliva collection from eight individuals at two timepoints allowed us to
compare the oral microbiome across individuals and changes between our two
collection timepoints. The interindividual diﬀerences in bacterial diversity and
abundance were small (fig. 12 A). The mean R2 was 0.82 between our donors.
Nonetheless, certain genera diﬀered up to tenfold between diﬀerent individuals.
We estimated relative diﬀerences in the total bacterial mass of the top eight
genera by summing their respective abundance estimates (fig. 12 B). It turns
out that this bacterial mass diﬀers up to threefold between diﬀerent donors. The
relative contributions of these top eight genera are remarkably similar across
individuals (fig. 12 C).
Given that the human saliva proteome clusters by sex in the first component of a
PCA we were interested whether there were substantial sex diﬀerences in the oral
microbiome. To this end, we aggregated male and female saliva metaproteomes
and compared the bacterial abundances between these groups. Bacterial abund-
ance was highly correlated with a coeﬃcient of determination of R2=0.94 (fig. 12
D), suggesting that there are only minor sex diﬀerences in the oral microbiome.
Yet, the abundances of oral bacteria changed drastically upon eating breakfast
and tooth brushing (fig. 12 E). The abundances of the most prevalent bacteria
reduced around 2.5-fold, while the reduction of low abundant bacteria was even
greater. The highly prevalent streptococci were reduced almost threefold (fig. 12
F). In the future it would be interesting to study the composition and changes
of the oral microbiome under diﬀerent conditions at greater depth.
A major advantage of our proteomics characterization of the microbiome over
genome sequencing approaches is the simultaneous determination of the human
saliva proteome. This allows to uncover interactions of the body and its micro-
biome on the protein level. For instance, our measurements revealed that the
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Figure 12: Interindividual and timepoint diﬀerences of the oral microbiome: A:
Typical scatter plot of the bacterial genera abundance between two donors. The eight most
abundant genera are highlighted in color. B: Relative quantification of the total bacterial
mass of the highlighted eight most abundant genera showing up to threefold interindividual
diﬀerences. C: The respective percentages of the involved genera are relatively constant across
individuals. D: Diﬀerences in genera abundance across the averaged quantities in males and
females were little. E: Mean bacterial abundance was markedly reduced after breakfast and
toothbrushing compared to waking. F: Bacterial abundance of the eight most abundant genera
in saliva compared between waking and postprandial. Adapted from [51].
human saliva proteome was enriched with proteins involved in bacterial defense
at waking, when bacterial abundance was high. This reflects the body’s attempts
to limit bacterial growth during the night. Thus metaproteomics approaches like
ours open up new ways to study host bacteria communication.
4 Discussion
4.1 Significance of MS based saliva proteomics and determination of the
oral microbiome
This work demonstrates that shotgun proteomics is now in the position to char-
acterize body fluids such as saliva at a depth of several thousand proteins. In
fact, our deep human saliva proteome represents the deepest body fluid proteome
recorded to date despite the fact that it was acquired in limited measurement
time. The quantification of so many proteins in saliva represents a valuable re-
source for the research community. As a matter of fact, several scientists have
contacted me since the publication of the saliva proteome asking whether I could
check the relative quantities of certain proteins in saliva for them.
The rapid workflow, that allows to determine a human saliva proteome from
collection to results in only 4 hours, seems particularly attractive. The measure-
ment time has reached time scales that seem compatible with clinical application
of MS-based protomics. This certainly renders saliva proteomics attractive for
studies on patient cohorts. Such studies could identify proteins that are of major
importance for maintaining oral cavity homeostasis. Potentially this could even
enable physicians to develop a risk score to determine the probability of a patient
to come down with cavity paving the way to personalized prevention.
In a second step, we demonstrated that proteomics can identify 50 bacterial
genera in saliva without the need to cultivate them first. We cross validated our
results by comparing them to next-generation sequencing data from the HMP
and MALDI-TOF bacteria typing that is used in routine clinical practice. In
both cases our proteomics data showed good agreement, indicating that shotgun
proteomics is a complementary method for microbiome analyses.
MS-based proteomics seems especially attractive for the study of pathogen host
interaction, since proteomics can provide host protein levels of the bacterial
environment at the same time. It might help us to understand the interplay
between microbial communities and our body on the systems level. In the case of
the oral cavity, we showed that the levels of antimicrobial proteins are elevated at
waking when the total bacterial mass is high. Yet, a better annotation of bacterial
sequences and complete bacterial databases are needed for this approach to reach
its full potential. The characterization of human microbiomes by means of MS-
based proteomics is still in very early stages, but it opens new frontiers for the
culture independent study of microorganisms.
The pace of development in MS-based proteomics is very high and does not
appear to slow down. This stirs hope that it could be of huge benefit for the
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medical sciences. While proteomics is already extensively used in research, it
has not found clinical application yet, except for its use in MALDI-TOF in
clinical microbiology. This thesis explored the potential of MS-based proteomics
for the characterization of bodyfluids and the oral microbiome. The following
two subsections will discuss some of the technological challenges that MS based
proteomics is still facing and highlight its potential clinical applications.
4.2 Technological challenges for clinical proteomics
At the moment there are three main technological obstacles for the use of MS-
based proteomics in clinical diagnostics beyond its use in biotypization of bac-
teria. These are the moderate sample throughput, the instability of the instru-
ment performance and the complexity of data interpretation.
Sample throughput in clinical chemistry is enormous. This is partly due to the
fact that most clinical parameters, proteins included, are determined in separate,
dedicated assays. However, even if we neglect that most patient samples are
tested for multiple readouts, the mere number of patients requires eﬃcient and
cheap measurement processes.
MS-based proteomics made stunning progress in sample throughput in the last
decade. Back in 2008 the milestone of the first complete characterization of the
yeast proteome took the authors three months to complete [3]. Nowadays, the
same results can be achieved in one hour with considerably better quantitative
accuracy [7, 15]. Nonetheless, such measurement times are still not suitable
for the analysis of patient samples other than for research. The limited sample
throughput also implies high costs, because the investment for instrumentation
amounts to several hundred thousand euro. However, the costs of the supplies
per sample are low, suggesting, that advances in sample throughput could render
MS-based proteomics cost eﬃcient.
The project on PASEF discussed in the appendix aims to overcome some of
the described limitations in MS technology. PASEF will substantially increase
proteomics coverage or - more importantly - allow to increase sample throughput
without losing sensitivity. Furthermore, it is fully compatible with multiplexing
strategies that use chemical labeling to parallel MS analysis. The combination of
these two approaches is likely to boost sample throughput at least twenty-fold,
potentially even more. In conclusion, the innovations that are already under way
as well as future developments are likely to overcome the present shortcomings
in sample throughput.
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The instability of instrument performance is one of the main reasons why MS
based shotgun proteomics has not been as widely adopted as might seem ap-
propriate. From Professor Mann’s lab’s experience, the combination of HPLC
and Orbitrap mass spectrometers deviate from the desired performance around
once per week. A certain expertise and experience is required to resolve these
issues [85] and presently most problems occur on the HPLC side [52]. For clinical
applications it would be favorable, if all MS-instrumentation operated robustly
guaranteeing reliable and reproducible results without the permanent checking
of an MS expert. As proteomics becomes more attractive for clinical application,
MS manufacturers will probably increase their eﬀorts to develop robust instru-
mentation. MALDI-TOF MS serves as a positive example, but it should not be
forgotten that it took decades to come up with an instrument that fits clinical
needs so well. Therefore, it seems justified to be carefully optimistic that MS
instrumentation suitable for non-expert clinical use will be developed in the next
decade.
Finally, the complexity of the MS readout seems to prevent its present use for
medical diagnostics. The simultaneous quantification of several hundred or thou-
sand proteins is certainly more diﬃcult to interpret than targeted analyses of
known disease markers. However, the amount of information of a proteomics
readout is likely to enable clinicians to diagnose diseases with greater certainty
and assess a patients condition with considerably higher accuracy. In this respect,
proteomics and genomics are much alike, though proteomics has the advantage
that it reflects both nature and nurture. It will therefore be necessary to develop
meaningful scores to reduce the information load and to draw conclusions from
these data. This will require some bioinformatic eﬀort and a lot of medical re-
search to define how the insights of proteomics are best used to improve human
health.
4.3 Perspectives for clinical proteomics
Given that MS based shotgun proteomics seems well on its way for clinical applic-
ation, its potential benefits shall be discussed briefly. Deep MS-based analyses of
the proteome could be very attractive for clinical microbiology. The character-
ization of the human oral microbiome by means of protoemics is among the first
projects of this kind and there is still much room for improvement. For example,
our approximate quantification of bacterial genera is by no means optimal. To
come up with more accurate and reliable results a direct comparison of quant-
itative metaproteomic data to quantitative metagenomic data would be needed.
This would allow to gauge diﬀerent metaproteomics quantification strategies and
compare them directly to well established methods.
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From a clinical standpoint, it would be highly desirable to extend the scope of
the mircobiome analysis down to the species or subspecies level. This is chal-
lenging given the huge dynamic range of protein abundance in such samples.
However, the concentration of a pathogen in an infection is in most cases con-
siderably higher than the concentration of bacteria from normal flora in healthy
individuals. This suggests that the characterization of a pathogen from a infec-
ted tissue might be a lot easier. It is therefore well possible that shogun mass
spectrometry will soon be able to characterize bacterial species down to the spe-
cies level without the need to culture them first. Patients suﬀering from sepsis
or severe pneumonia could substantially benefit from faster culture independ-
ent typization, because an early specific antibiotic therapy is crucial for patient
outcome in these cases.
Likewise, the proteomics approach developed in this thesis is amenable to patho-
gens that cannot be cultured or grow slowly, i.e. mycobacteria. It would therefore
be highly desirable that clinical samples from such infections are analyzed with
MS based shotgun proteomics. This would allow to optimize the method for
clinical needs and to evaluate its clinical utility.
In the future it might even be possible to directly quantify the proteins that
convey antibiotic resistance. Given the rising resistance rates in many health
care units fast and reliable antibiotic resistance testing is becoming increasingly
important. The quantitative accuracy of proteins responsible for antibiotic resist-
ance could be raised by targeting the respective peptide precursors specifically.
Along these lines, it would even be possible to design dedicated MS methods
for resistance testing. Since shotgun proteomics omits the cultivation of bac-
teria, this form of resistance testing is likely to reflect the in vivo situation
more accurately than testing of bacterial cultures. In addition, the impact of
antibiotic treatment on a pathogen and on the remaining human microbiome
could be studied in detail with this technology. For example, the pathogenesis
of pseudomembranous colitis from Clostridium diﬃcile during antibiotic ther-
apy could be investigated on the systems level. Understanding this process in
detail might enable physicians to develop new strategies to prevent this undesir-
able complication of antibiotic therapy. It seems furthermore ideally suited to
investigate the interactions of the human body with its microbiome.
The clinical potential of MS based shotgun proteomics is not limited to microbi-
ology. The longitudinal profile of the weight reduction cohort from the project
in the appendix revealed that a surprisingly large proportion of plasma proteins
shows greater variation between individuals than in one individual over time.
This suggests, that personalized medicine should seek to define reference val-
ues for individuals separately. Pathological deviations form homeostatic baseline
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levels could thus be detected with considerably higher accuracy compared to de-
viations form a much broader window of reference values of a standard cohort.
Ultimately, patient tailored diagnostic tests could make medicine more precise
and increase the informative value of known biomarkers. Such patient specific
baseline levels would have to be determined for a plethora of functional proteins,
a task for which MS-based proteomics seems ideally suited.
Furthermore, the simultaneous changes of functionally related proteins are likely
to increase diagnostic certainty and will help to resolve problems due to multiple
hypothesis testing. The diﬃcult interpretation of the proteomics readout could
be simplified by calculating scores for diseases based on the levels of several pro-
teins. Body fluid proteomics therefore seems ideally placed for routine clinical
health checkups, because it could asses an individual’s well being by analyzing
thousands of functionally related and unrelated proteins and provide a com-
prehensive picture of the homeostasis of diverse organ systems and metabolic
functions. The saliva proteome measurements revealed that such measurements
should ideally take place at the same time of the day since protein levels change
during the day. The minimal amounts of sample that are needed for proteomics
measurements are another major advantage of this sort of measurement.
Yet, for all these potential benefits of clinical proteomics to be realized, more
research will be necessary. We will learn a lot about the human body in the
course of this quest and MS based proteomics is likely to play a major role in
it.
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Appendix
A Multiplying sequencing speed using Trapped Ion Mobility
Mass Spectrometry
A.1 The problem of inaccessible peptide species in data-dependent LC-
MS/MS
An important prerequisite for the clinical application of MS-based proteomics is
eﬃcient measurements of proteomes at great depth. Despite huge progress in this
area in the last years, even better coverage of the proteome would be desirable.
Take the bacterial species in saliva as an example. If more low abundant pro-
teins could be measured, some of the less abundant microorganisms would not
escape detection and bacterial genera could potentially be diﬀerentiated down
to the species level. Similarly, the human plasma proteome in the weight loss
study described below covered around 437 of the most abundant plasma pro-
teins. However, many important low abundant plasma proteins and peptides are
missed, such as prostate specific antigen, troponins or thyroid-stimulating hor-
mone. Consequently, technological progress would facilitate the clinical applica-
tion of MS-based proteomics. The project described in the following establishes
a new operation mode on a prototype mass spectrometer that could substantially
increase sequencing speed and boost the depth of analysis in this way.
The determination and quantification of several thousand protein species from
one sample cannot be achieved by measuring all the tryptic peptides simulat-
neously. Instead it has become a standard to separate peptides by liquid chroma-
tography first and measure them successively. Hence, diﬀerent peptide species
are measured independently depending on their elution time. This way, peptides
are separated in two dimensions with their HPLC elution time as one axis and
their m/z ratio as the other axis. This is frequently illustrated by plotting the
detected peptides in a m/z-retention time plane. Ideally, this plane is homo-
geneously populated by peptides so that the overlap of proteins is kept minimal
along both axes. Many peptide species however elute simultaneously and cannot
all be sequenced individually by MS/MS. Data suggests that only 16% out of
100,000 peptide features eluting in the course of a 90 min HPLC gradient are
targeted for MS/MS scans, leaving the majority of peptides undetected [86].
Despite advances in sequencing speed and resolving power [87] this situation has
not changed much - partially, because the faster acquisition of MS/MS spectra
decreases the number of ions detected per MS/MS scan. The instrument method
sequential window acquisition of all theoretical mass spectra (SWATH) aims to
overcome the problem of inaccessible precursors by cycling through consecutively
broader mass windows and fragmenting all peptides per window in parallel [21].
A major disadvantage of this strategy is that it renders the previously discussed
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multiplexing with iTRAQ or TMT impossible, because the reporter ion ratios of
individual precursors are lost. Even if SWATH is not used and the mass selection
window for MS/MS scans is kept small, the percentage of the precursor ion among
all ions in the selection window can be small. This increases the complexity of
peptide identification and limits quantification accuracy in multiplexing. It is
therefore desirable to have a big precursor ion fraction among all ions in the
selection window.
Trapped ion mobility spectrometry (TIMS) [88] is a new type of ion mobility mass
spectrometer only described in 2015. In a nutshell, it is a mass spectrometer that
measures an additional physical property of the analytes, their ion mobility. The
ion motility is a measure for how fast an analyte travels in a carrier gas and is
consequently a function of its collisional cross section. TIMS determines the ion
mobility using an ion trap. This oﬀers several advantages over conventional ion
mobility spectrometry. In particular, it allows to fragment several peptides in
parallel while still correctly assigning all fragments to their peptides of origin.
This is possible, because the ion mobility of a peptide is determined in addition
to its m/z ratio and its elution time. The described mode of operation was coined
Parallel Accumulation-Serial Fragmentation (PASEF) and enables very accurate
measurement of the reporter ion ratios since the peptides that are fragmented in
parallel diﬀer in their ion mobilities. In the following, PASEF will be explained
and discussed in detail as well as its implementation on a TIMS prototype. Parts
of this work were published in the Journal of proteome research [53].
A.2 Instrument characteristics of a TIMS-QTOF mass spectrometer
This subsection introduces the instrument prototype on which the PASEF method
can be implemented. It diﬀers substantially from conventional ion mobility spec-
trometers and oﬀers additional set screws to optimize MS measurements.
The PASEF method was realized on a prototype TIMS-QTOF mass spectro-
meter, which is schematically depicted in figure A.13. TIMS is an advancement
of ion mobility spectrometry (IMS) [88]. Compared to normal MS, IMS sep-
arates molecules based on their ion mobility in addition to the separation by
hydrophobicity on the HPLC and the separation by mass. Traditionally, this
comes at the cost of losing ions along the long ion mobility tunnel.
By reversing the flow of the drift gas and trapping the ions along an increasing
electric field the ion mobility can be determined in a compact setup with better
ion control. To this end, peptides are separated via HPLC and ionized via ESI
before entering the instrument through a glass capillary (fig. A.13 A). They
are subsequently deflected by 90  to get rid of uncharged molecules and enter
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the TIMS tunnel. While the ions are confined radially by a radio-frequency
quadrupolar field, they are dragged forward by the atmospheric drift gas (fig.
A.13 B). An increasing electric field strength directed in the opposite direction
prevents the ions from immediately passing the tunnel and causes ions with high
mobilities to accumulate at the entrance of the tunnel and ions with low mobility
at the exit of the tunnel (fig. A.13 B). Once enough ions are accumulated the
electric potential along the gradient is reduced over time and the ion packages
elute from the TIMS tunnel with low mobility ions eluting first. The eluting
ions are kept in focus and directed to an analytical quadrupole that can be used
as collision cell and to select ion species for MS/MS scans. Subsequently, the
ions are accelerated orthogonally into the field free drift region of the flight tube
of the TOF mass analyzer. The mass analyzer is essentially the same as in the
Bruker impact II instrument [20].
The potential of the TIMS tunnel therefore changes periodically. During a full
period length of this cycle several TOF spectra are recorded at a frequency of
8.7 kHz. All the TOF scans that are measured in such a period length together
define a ‚TIMS scan‘. The signal to noise ratio of an individual TIMS scan can
be insuﬃcient, hence requiring to add several TIMS scans to come up with a
reasonable TIMS-MS spectrum. Such a spectrum displays the signal intensity of
an ion species in the ion mobility-m/z-plane. At present, the precursor selection
is based on the intensity of the ions in the m/z spectrum regardless of their ion
mobility. Hence, for the precursor selection all TOF scans from one TIMS scan
are summed and the top N ions are selected for fragmentation.
The selection of ions in the TIMS device has two advantages compared to normal
MS/MS spectra. First, although there are several diﬀerent ion species in the m/z
selection window, these ion species are separated in ion mobility. Consequently,
the precursor ion fraction can be very high when only the ions with the ion mo-
bility of the precursor peptide are considered. This advantage is not exclusive to
TIMS, but occurs in normal IMS as well and it is well established that it renders
benefits for peptide identification [89]. If one only uses the reporter ions in the ion
mobility window of the precursors, quantification in multiplexing experiments is
hence very accurate. This feature of TIMS is called ratio compression.
The second advantage arises from the accumulation of ions in the TIMS tunnel.
Since ions are accumulated, their signal intensity is very high when they elute.
Instead of recording the ion signal continuously, the TIMS tunnel compresses the
signal of an ion into the short time interval when it elutes, resulting in a better
signal to noise ratio.
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Figure A.13: TIMS-QTOF mass spectrometer: A: The TIMS-QTOF consists of three
main components, the TIMS tunnel, the quadrupole filter and the TOF mass analyzer. The
ions enter the instrument through the entrance funnel on the left, exit the TIMS tunnel in a
controlled manner depending on their ion mobility, pass through the quadrupole filter and end
up in the flight tower. B: The TIMS cell itself consists of the green entrance funnel on the
left, the purple TIMS tunnel, where the ions are accumulated, and the green exit funnel on
the right. The tiny bars in the profile represent ring electrodes in a quadrupolar arrangement
that are coupled to one another by resistors. This setup allows to realize the linear electric
potential in (C) along the z axis while confining the ions in the x-y-plane via an oscillating
quadrupolar field. C: First, ions are trapped in the TIMS tunnel by a forward directed gas
flow and a linearly rising potential that exerts an opposing electric force (1). Subsequently, the
ions serially elute from the TIMS tunnel depending on their ion mobility as the electric filed
decreases (2). Adapted from [53].
A.3 Principle of Parallel Accumulation-Serial Fragmentation
The separation of ions in the MS/MS selection window by ion mobility is already
beneficial. However, the precursor of interest only elutes in a very small ion mo-
bility window and most of the other TOF scans in the respective TIMS scan
can be of little value, especially if they contain only low intensity signals. For
the described case, it is more eﬃcient to rapidly change the selection window
so that diﬀerent precursors of diﬀerent ion mobility can be selected within one
TIMS scan. We call this operation mode ‚Parallel accumulation - serial frag-
mentation‘ (PASEF). A scheme of this operation mode is depicted in figure
A.14.
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In PASEF several precursors are measured in one TIMS scan. Since the m/z
values and the ion mobilities of the precursors are known from the TIMS-MS
spectrum, a serial precursor selection of ion mobility and m/z windows takes
place with the limitation that the ion mobility windows must not overlap. Also,
PASEF requires very short switching times of the selection quadrupole. In this
way, the full signal intensities of several precursors are measured in a single TIMS
scan, since the precursor intensities are compressed into tiny non overlapping ion
mobility windows by the accumulation in the TIMS tunnel. This eﬃcient use of
available ions can be used in two ways. Either the speed of MS/MS acquisition is
increased by the number of targeted precursors per TIMS scan or the sensitivity
is increased by the same factor by targeting the same precursors several times.
One can also use a combination of the gains in sensitivity and speed.
Figure A.14: Comparison of normal TIMS-MS/MS with PASEF: The normal TIMS-
MS/MS method is illustrated in the top panel. One precursor is selected for fragmentation
with collision induced dissociation (CID) in the entire TIMS scan. The lower panel shows the
serial selection of diﬀerent isolation windows for precursors of diﬀerent ion mobility in a single
TIMS scan. This way all four available ions can be used for fragmentation in one TIMS scan.
Adapted from [53].
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A.4 Realization of Parallel Accumulation-Serial Fragmentation
The PASEF method requires a rapid determination of the precursors that are to
be selected for MS/MS scans and a fast switching of the quadrupole. The chroma-
tographic peak width for 90-min gradients in shotgun proteomics is around 7 s in
Professor Mann’s laboratory as determined by the full width at half-maximum
(FWHM) definition [20]. The acquisition of the MS spectrum takes around
0.2 s, the acquisition of one MS/MS scan takes 60ms for a data-dependent top17
method on our QTOF instruments. Thus, the entire acquisition cycle for a top
17 method amounts to 1.3 s. Since an individual TOF scan only lasts 110µs, each
MS or MS/MS spectrum consists of the sum of several hundred TOF scans.
These figures show, that the selection quadrupole in the QTOF instrument
switches its isolation window approximately every 60 ms. Given that ion mo-
bility peaks in our TIMS tunnel have half widths (FWHM) of around one mil-
lisecond, the PASEF method requires the selection quadrupole to operate on
a much shorter timescale. The build-up time of the power supplies enables to
change the isolation window in the desired m/z range within less than 1.5ms.
To capture the entire ion mobility peak at the present resolution of the TIMS
tunnel an isolation time of 2.5 to 4ms is adequate. Consequently, up to 12 -
20 times more MS/MS spectra should be measurable using PASEF without any
loss in sensitivity. It seems unlikely that enough diﬀerent precursors exist to
use all these additional MS/MS for the identification of additional precursors.
Instead they could be employed to improve identification and quantification by
measuring the same precursor several times to obtain better spectral quality and
more accurate intensities.
Presently, the instrument controller is unable to calculate and apply the respect-
ive isolation windows at the desired speed of less than 1.5 ms. We still wanted
to demonstrate the PASEF method in a proof of principle experiment on our
present set-up. For this reason we first determined the desired isolation window
and elution time from a TIMS precursor scan and then applied the switching
times and the isolation window separately via the instrument controller.
In the future, the real time field-programmable gate array will calculate and
set the respective TIMS and isolation windows in real time on the fly. This
requires improvements in the accurate peak interpretation and 4D precursor
determination in real time (fig. A.15).
48
A.5 Parallel Accumulation-Serial Fragmentation in the analysis of a complex peptide mixture
Figure A.15: Hardware requirements for PASEF method: The major hardware compon-
ents of a protoeomics LC-TIMS-MS/MS setup and their connections are depicted schematically.
The green and blue flow lines represent exisiting and future implementations that are required
to realize the indicated time scales. GS/s, Giga-samples per second. Adapted from [53].
A.5 Parallel Accumulation-Serial Fragmentation in the analysis of a com-
plex peptide mixture
Though the hardware requirements for the real time operation of PASEF re-
main to be realized, we aimed to demonstrate the benefits of this method for the
analysis for complex peptide mixtures in our proof of principle experiment. We
therefore injected a mixture of digested alcohol dehydrogenase (ADH), bovine
serum albumin (BSA), enolase and phosphorylase b by direct infusion to mimic
the simultaneous elution of several peptides from the HPLC. Without the separ-
ation of these peptides by their ion mobility, the resulting mass spectrum would
be very complex. The resulting two dimensional TIMS-MS spectrum is depic-
ted in figure A.16 A. Note that the m/z spectrum without the separation in
ion mobility is simply the projection of the horizontal ion mobility axis on the
vertical m/z axis. Due to their higher collision cross section, heavier particles
elute earlier and show lower mobility values. Consequently, m/z and ion mo-
bility are inversely correlated to some extent. Furthermore, diﬀerently charged
ions populate diﬀerent regimes of the TIMS-MS spectrum in figure A.16 A. This
correlation implies that a reasonably high resolution in ion mobility is necessary
for the separation in ion mobility to yield additional information.
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Figure A.16: TIMS-QTOF measurement of a directly infused complex peptide mix
from digested ADH, BSA, phosphorylase b and enolase: A: TIMS-MS spectrum from
a full MS scan. The projection on the right represents the mass spectrum obtained without
mobility separation. B: Serial isolation of four precursors with non-overlapping ion mobility
peaks. C: PASEF of the four precursors in B. The resulting fragemnts remain separated in
ion mobility and the detected intensities correspond to the intensities registered in the normal
TIMS operation mode. D: The arrival time distribution of the summed fragments from C
reveals that more non overlapping ion mobility windows could have been chosen. Adapted
from [53].
In our experiment we set the TIMS tunnel time to ramp down the TIMS tunnel
gradient to 50ms. This was suﬃcient to realize a resolution (FWHM) of above
40 that separated many ions of equal m/z. Next, we selected four precursors with
m/z 810.3 (1), 714.3 (2), 559.3 (3) and 560.6 (4) and selected the corresponding
switching times for the precursor selection by hand. The resulting PASEF scan
in figure A.16 B shows the isolation of the entire mobility peak of each of the
four precursors following their parallel accumulation. Note that precursors (3)
and (4) only diﬀer in one Thomson, hence they would probably end up in the
precursor isolation window of one another. Their separation in ion mobility
allows to diﬀerentiate these two precursors. The feature marked with an asterisk
represents two singly charged ion species that belong to the singly charged ion
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population and were only isolated, because the precursor isolation window was
set to the isolation of feature (1) from the beginning.
Subsequently, we determined the MS/MS spectra of the four selected precurs-
ors using PASEF. As figure A.16 C demonstrates, the ion mobilites are pre-
served despite the fragmentation of the precursors. The fragment spectra al-
lowed us to identify all our precursors, namely VLGIDGGEGKEELFR (1) from
enolase, HLQIIYEINQR (2), VAAAFPGDVDR (3) and IGEEISDLDQLRK (4)
from phosphorylase B. Figure A.16 D shows that the respective fragment ion
peaks were only around 3ms wide allowing to select more than ten precursors
during the 50ms ramp time.
We also wondered whether these results would hold true, if we selected more
diﬀerent precursors across the entire mass range from 418 to 956 Th and across
the entire mobility range with elution times ranging from 17 to 44ms with an
average half width of 0.8±0.2ms. To this end we chose ten sets consisting of
four precursors each and performed the experiment from above on all sets. The
results are summarized in Table A.1 in the appendix. The full signal intensity
was recovered compared to the normal TIMS method even though the acquisition
of MS/MS spectra was four fold faster.
A.6 Relevance of Parallel Accumulation-Serial Fragmentation for clinical
proteomics
Ion mobility spectrometry combined with a mass spectrometer provides an ad-
ditional separation dimension. Consequently, it could be of great value for the
analysis of complex protein mixtures such as human tissue or body fluids. We
introduced the PASEF method that is compatible with any ion mobility mass
spectrometer with a scan speed in the sub-millisecond range. In our compact
TIMS-QTOF analyzer, we managed to select several precursors for fragmenta-
tion in a single 50ms ion mobility scan, hence demonstrating PASEF for the first
time.
Since the signal intensity was not decreased due to the serial fragmentation,
PASEF could increase the sequencing speed around 10-fold without loss in quan-
titative accuracy. These gains in sequencing speed are probably best used by a
combination of targeting more precursors and targeting low intensity precur-
sors several times. By contrast to other methods that target several precursors
simultaneously, such as SWATH, PASEF is fully data dependent. This implies
that the mass isolation window targets a single precursor. PASEF is therefore
suitable for chemical labeling strategies such as iTRAQ or TMT. This would
allow to multiplex the analysis of patient samples. For PASEF to be used for
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entire proteomics samples, several improvements in the hardware communication
of our TIMS-QTOF analyzer remain to be implemented. Once these challenges
are met, PASEF is likely to render faster and more in depth analysis of patient
proteomics samples possible.
A.7 Materials and Methods of Parallel Accumulation-Serial Fragmenta-
tion
A profound description of the TIMS analyzer used has been published elsewhere
[88, 90]. We used nitrogen as a bath gas at room temperature and the pressure
diﬀerence between the entrance funnel and the exit funnel was 1mbar creating a
gas flow velocity of around 1.5 · 102m/s. The ion accumulation time was set to
50ms in the in instrument control software OtofControl (Bruker Daltonik, Bre-
men, Germany). The electric field gradient was realized by setting the entrance
of the TIMS tunnel to - 180V and the exit to -40V. The time for decreasing the
slope of the ramp was set to 435 TOF scans of 115µs each, resulting in around
50ms.
Purified, digested standard solutions of ADH, BSA, enolase and phosphorylase
b from Waters GmbH (Eschborn, Germany) were solved separately in 0.1%
formic acid and diluted to a concentration of 10 pmol/µL each. These solutions
were mixed to form an equimolar solution that was subsequently diluted in 50%
water/50% acetonitrile/0.1% formic acid (v/v/v) to a final concentration of
100 fmol/µL. This solution was directly infused into our TIMS-QTOF prototype
at a flow rate of 3µL/min to simulate the simultaneous elution of several peptides
from an HPLC.
The precursor masses for PASEF were determined from a full TIMS-MS scan.
Subsequently, the appropriate isolation windows, switching times and collision
energy were manually set at the instrument controller. We chose 3Th for the
isolation window with and collision energies between 30 to 60 eV depending on
the m/z of the respective precursor. The resulting ion mobility-mass spectra
were analyzed in a prototype software of Bruker’s DataAnalysis.
52
B Eﬀects of sustained weight loss on the human plasma pro-
teome
B.1 Evaluating weight loss eﬀects on the body from a systems perspect-
ive
The prevalence of severe obesity in the Western world is increasing at a dramatic
pace. In US children, numbers have climbed from 4% during 1999-2004 to 6%
during 2011-2012 [91, 92]. This represents a major public health burden, giving
rise to serious secondary diseases such as type 2 diabetes, hypertension or dys-
lipidemia among many others [93, 94]. The best treatment for obese patients
suﬀering from the metabolic syndrome is sustained weight reduction [95]. Yet,
the underlying mechanisms of the benefit of weight loss in obese patients are
insuﬃciently understood and so is the extent to which they vary between indi-
viduals [96]. The metabolic health status of an individual is commonly evaluated
by plasma metabolites and plasma proteins such as cholesterol, blood glucose,
diverse lipoproteins, C-reactive protein or HbA1c [97]. Given that cholesterol
and triglyceride levels correlate well with plasma proteins like apolipoprotein A1
and B, plasma proteomics seems uniquely positioned to study the processes dur-
ing weight loss from a systems perspective. Although it is well established that
weight loss leads to substantial changes of plasma proteins like the sex hormone-
binding globulin [98], the impact of weight loss on the plasma proteome has not
been assessed globally, but only protein by protein with antibody based meth-
ods.
The unbiased quantitative account of a multitude of plasma proteins by MS-
based proteomics has fascinated researchers and clinicians since the early days
of this technology [99]. However, the huge dynamic range of plasma makes it
particularly challenging to analyze the plasma proteome at suﬃcient coverage for
an entire study population (compare subsection 2.2 and [100]). The substantial
progress in MS technology in recent years [101, 102] motivated Professor Mann’s
laboratory to develop an automated, relatively high-throughput workflow that
allows the reproducible, quantitative analysis of hundreds of plasma proteomes
[54]. In this project, we wanted to evaluate the utility of our workflow by meas-
uring the proteomes of 43 individuals at seven time points over 14 months from
a longitudinal prospective cohort study on sustained weight loss [103]. This
represents the first global analysis of the impact of weight loss on the plasma
proteome.
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B.2 Study design and plasma proteomics analysis
The study aimed to assess the eﬀect of weight loss on the human plasma protein.
An existing randomized controlled trial on 52 obese individuals seemed ideally
suited for that purpose. It originally investigated the eﬀect of GLP-1 receptor
agonist treatment on maintaining body weight loss and free leptin levels [103].
Briefly, 52 healthy individuals with body mass index (BMI) 30 - 40 kg/m2 aged
between 18 and 65 years were recruited for the study. Subjects completed an
8-week weight loss program (800 kcal per day; Cambridge Weight Plan, Corby,
UK [104]), loosing 12% body weight on average. Following the weight loss phase,
participants were randomized into two groups, 27 received the GLP-1 receptor
agonist liraglutide 1.2mg per day and the remaining 25 persons served as control
group. Both groups were monitored for one year with a total of 13 visits with the
study dietitian. Each of the 43 participants that adhered to the study protocol
for the entire study period donated fasting blood samples at week -8, week 0,
week 4, week 13, week 26, week 39 and week 52 (fig. B.17 A). Since neither
the original study nor our analysis revealed significant diﬀerences between the
treatment and control group we did not diﬀerentiate between the two study arms
in our analysis.
This resulted in 319 plasma samples each measured in quadruplicates to obtain
highly accurate label-free protein quantification. In order to increase the depth
of our proteomic coverage, we created a MS plasma proteome library that en-
ables the identification of precursors not targeted for fragmentation. This is
achieved by comparing MS spectra recorded at equal elution times between runs
and checking whether the precursors in questions were targeted for MS/MS in
other runs [58]. We therefore took blood from three healthy male and female
volunteers and depleted these samples twice with antibodies for the top 20 most
abundant plasma proteins. Subsequent sample processing was identical to the
study samples. Note that this depletion leads to substantial distortions of relat-
ive plasma protein levels due to unspecific binding. It is therefore not suitable
to obtain an unbiased quantification of the plasma proteome. It is however well
suited for the creation of a deep library that improves precursor identification.
Altogether, the study measurements and the creation of the plasma proteome lib-
rary amounted to 1294 MS measurements - to our knowledge the largest plasma
proteomics study in a clinical framework. It took us 10 weeks to complete the
data acquisition with a measurement time of 30 minutes per sample if no com-
plications occurred. The reproducibility of our measurements was high with a
mean correlation coeﬃcient R2 of 0.97 for the quadruplicate measurements. We
identified 737 plasma proteins across all study participants excluding potential
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contaminants such as keratins. On average 437 proteins were detected per indi-
vidual with a standard deviation of 23.
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Figure B.17: Study design and plasma proteomics workflow: A: A total of 52 healthy
obese study participants lost 12% of their body weight on average during an 8 week period
of caloric restriction. This acute weight loss was followed by a weight maintenance period of
52 weeks by 43 individuals. Blood samples from each participant were taken at the indicated
timepoints. B: An automated liquid handling platform prepared quadruplicates of all samples
for LC-MS/MS measurement on a Q-Exactive HF mass spectrometer. We optimized the data
analysis in MaxQuant with a matching library and created plasma proteome profiles for all 52
individuals. Adapted from [52].
B.3 Interindividual variation of the plasma proteome
The five follow up plasma samples per donor after the acute weight loss lead us
to investigate how constant plasma protein levels are in a one-year period and
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how they vary between individuals. We compared the plasma protein levels of all
448 proteins that were quantified at all five time points for at least one individual
across all participants. Remarkably, 25% of these proteins diﬀered more than
five-fold from the group average and 69% proteins diﬀered more than two-fold
(fig. B.18 A).
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Figure B.18: Personalized plasma protein levels across the five longitudinal plasma
samples: A: We calculated the coeﬃcients of variation (CVs) for all proteins across all five
post weight loss samples in all participants. The percentage of proteins below the certain CV
thresholds are given. B: CVs of quantified proteins across the five post weight loss samples
from participant four plotted against the fold change diﬀerence compared to the average label
free quantification (LFQ) intensity of the study cohort. The blue boxes contain proteins with
a CV below 30% and a fold change above 5, hence satisfying our criteria for individual specific
proteins. C: LFQ Intensities of seven highly individual specific plasma proteins of all 43 par-
ticipants across all five longitudinal samples. A2M: Alpha-2-macroglobulin, PZP: Pregnancy
zone protein, IGJ: Immunoglobulin J chain, LPA: Apolipoprotein(a), FETUB: Fetuin-B, CRP:
C-reactive protein, GDI1/GDI2: Rab GDP dissociation inhibitor alpha/beta. Adapted from
[52].
While some of these interindividual diﬀerences are explained by inaccurate quan-
tification of low abundant proteins, numerous proteins showed substantial inter-
individual diﬀerences despite low CVs across the five measurement time points.
It turns out that 46% of all proteins across all participants deviate by more
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than two fold from the group average while having CVs below 30% across the
five samples. Proteins fulfilling these criteria for a certain participant will be re-
ferred to as individual specific for this individual in the remainder of this thesis.
The concept of individual specific proteins can be illustrated by pregnancy zone
protein (PZP) that was 26 times more abundant in donor 4 than in the group av-
erage but remained constant over one year with a CV below 10% (fig. B.18 B).
Other typical individual specific proteins detected in all participants included
↵-2-macroblobuline, lipoprotein (a), immunoglobulin J chain, fetuin-B and C-
reactive protein (fig. B.18 C). In the case of lipoprotein(a), the variation is
genetically explained by the diﬀerence in the number of kringle domains that
reduce secretion into the bloodstream [105]. Other proteins hardly varied across
individuals or time indicating that a strict control of their levels is crucial for
body homeostasis. These proteins were serum albumin, complement factor C3,
vitamin D-binding protein, kininogen-1, hemopexin, complement factor H and
clusterin among others.
B.4 Impact of weight loss on the plasma proteome
The follow up blood donations in the study allowed to investigate both the acute
and the long term eﬀects of weight reduction on the plasma proteome. To eval-
uate the immediate eﬀect of weight loss on the plasma proteome, we calculated
a one-sample t-test with 5% FDR after Benjamini-Hochberg correction of all
detected proteins comparing the samples of week -8 to the samples of week 0.
It revealed that 63 proteins were significantly decreased and 30 were signific-
antly increased upon weight loss (fig. B.19 A). The fold changes were moderate
compared to stimulation experiments in cell culture as expected given the homeo-
static control of blood constituents. For example, levels of Albumin, the main
plasma protein, were relatively increased by 8%. Apolipoprotein F (APOF) and
Inter-↵-trypsin inhibitor heavy chain H3 (ITIH3) changed more drastically with
an increase of 37% and 34% respectively. The most significant reduction in rel-
ative protein abundance upon weight loss was recorded for Pigment-epithelium
derived factor (SERPINF1) that changed by -16% and is known to be secreted
by adipocytes [106]. By contrast, the greatest significant increase in relative
abundance was observed for sex hormone binding globulin (SHBG) with 117%.
This is in accordance with previous analyses targeting SHBG specifically [98].
Importantly, there were always exceptions of these regulatory changes for a hand
full of individuals, suggesting that complex metabolic transformations are best
studied on the systems level rather than studying just one single biomarker (fig.
B.19 B).
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Figure B.19: Personalized plasma protein levels: A: t-test p-values plotted against fold
change before (week -8) and directly after weight loss (week 0) of plasma proteins (5% FDR
after Benjamini-Hochberg correction). B: Label free quantification (LFQ) changes on an in-
dividual basis are displayed for certain proteins with the median change indicated in the top
right corner in red. APOF: Apolipoprotein F, ITIH3: Inter-↵-trypsin-inhibitor heavy chain
H3, SHBG: Sex hormone binding globulin, SERPINA1: ↵-1-antitrypsin, IL1RAP: Interleukin-1
receptor accessory protein, SERPINF1: Pigment-epithelium derived factor, APOB: Apolipo-
protein B-100, AFM: Afamin, SAA1: Serum amyloid A-1 protein. Adapted from [52].
Previous investigations discovered that the levels of freely circulating cortisol
decrease upon weight loss [98]. Although we did not determine steroid hormones
with our method, we still observed indirect signs of this change in the form of a
12% increase of the Corticosteroid-binding globulin (SERPINA6), which binds
80% of circulating cortisol. In addition, the increase in Albumin is likely to
contribute to the reduction in freely circulating cortisol.
Next, we investigated the chronic eﬀects of sustained weight loss on the plasma
proteome. We found 84 proteins that were changed with high significance (p< 5 · 10 4)
between the baseline level and at least one timepoint after weight loss in the one
year weight maintenance period. They clustered into seven groups depending on
their adaptation to the acute weight loss (fig. B.20).
Proteins from the first group markedly decreased in response to the weight loss,
but steadily turned back to normal in the weight maintenance period. Hence,
they seem to remain in a steady state irrespective of the body weight, but de-
crease upon a sudden reduction in energy supply.
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Figure B.20: Long-term impact of sus-
tained weight loss on the plasma pro-
teome: Hierarchical clustering of Z-scored la-
bel free quantification intensities for highly
singnificant proteins (p< 0.0005). The time
course of protein abundance of the seven res-
ulting clusters is dispalyed in the inlets with
color coding for the distance from the center of
the respective cluster. The color coding of the
gene names on the left mark inflammatory pro-
teins in red, serine protease inhibitors in brown,
members of the complement system in orange,
apolipoproteins in blue, anti inflammatory pro-
teins in purple and steroid transporting proteins
in green. Adapted from [52].
They included APOA4, Afamin, a
vitamin E transporting protein and
Serum paraoxonase (PON1). PON1
is known to be less active in obese
children and adults [107].
The second group of proteins
decreased upon weight loss and
maintained at a low level through-
out the one year follow up period.
It consisted mainly of inflammat-
ory proteins (CRP, SAA1, SAA4
and ORM2) and apolipoproteins
(APOA2, APOB, APOC3), both of
which will be discussed in detail in
the next subsection.
Similar to the second group, the pro-
teins in group four decreased upon
weight reduction, but it took them
several months to arrive at a new state
of equilibrium, now on a lower abund-
ance level. The clustering is biolo-
gically plausible, because related pro-
teins ended up in the same or adja-
cent groups indicating that they were
collectively regulated. Interestingly,
the levels of neurophilin-1 (NRP1) in-
creased almost twofold in the first
year after acute weight loss and so
did the levels of Vitamin D-binding
protein. By contrast, the proteogyl-
can 4 (PRG4), that occurs in joints
decreased by -19% on average and
heparin cofactor 2 (SERPIND1), a
thrombin inhibitor, by -9%.
B.5 Eﬀects of weight loss on the apolipoprotein profile
Apolipoproteins facilitate the transport of insoluble fats in the body. Con-
sequently, their levels are of major importance to diagnose and monitor lipo-
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metabolic disorders that are highly prevalent worldwide and a major contributor
to cardiovascular morbidity [108]. Our plasma measurements revealed longitud-
inal profiles of 18 diﬀerent lipoproteins (fig. B.21). LPA levels showed the largest
increase of 95% upon the acute weight loss and maintained elevated through-
out the observational period. Members of the Apolipoprotein C family (APOC1,
APOC2, APOC4) collectively decreased permanently to about 70% of their base
level. Other lipoproteins such as APOF responded with an increase to the acute
weight loss, but reverted to base levels in the course of the one year mainten-
ance period. Similarly, APOA4 acutely decreased by 36%, but also returned to
baseline within a year.
Given this diﬀerential regulation of diﬀerent lipoproteins, we subsequently cor-
related the observed changes with the changes of cholesterol, triglyceride, gluc-
ose, high density lipoprotein (HDL), low density lipoprotein (LDL) levels and
BMI. APOB strongly correlated with LDL (R2=0.72) as expected since a LDL
forms around one APOB molecule. The question whether APOB might there-
fore be a more accurate measure for cardiovascular risk assessment and pre-
vention than LDL is the subject of ongoing debates [109]. Likewise, the levels
of APOA1 were highly correlated with HDL levels (R2=0.64). Furthermore,
APOF was negatively correlated with triglyceride levels (R2= -0.50) and APOB,
APOC2, APOC3, APOC4 and APOE were positively correlated with trigly-
cerides (R2=0.33, 0.45, 0.52, 0.38 and 0.45 respectively).
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Figure B.21: Longitudinal apolipoprotein profiles of acute weight loss: Mean normal-
ized label free quantification (LFQ) intensities for 18 apoliporproteins are plotted across the
entire observation period. LFQ values were normalized to the initial levels before weight loss
(week -8) and the bars represent the standard error of the mean. The coloring refers to the
clusters in figure B.18. Adapted from [52].
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B.6 Eﬀects of weight loss on inflammatory proteins
Weight loss resulted in a marked reduction of inflammatory proteins, in partic-
ular acute phase proteins. CRP, SAA1, SAA4 and ORM2 all clustered in group
2 of our cluster analysis, meaning that they were immediately reduced following
acute weight loss (compare fig. B.20). The reduction of the two cardiovascu-
lar risk markers SAA1 and CRP was particularly pronounced with -43% and
-35% respectively, compared to the slower reduction of ORM1, Serum amyloid
P-component (APCS) and Lipopolysaccharide-binding protein (LBP) (-16%, -
10% and -16% respectively at week 52). Other acute phase proteins such as
Alpha-1-antitrypsin (SERPINA1) and Alpha-1-antichymotrypsin (SERPINA3)
were upregulated immediately after weight loss, but declined in the weight main-
tenance period.
Subsequently, we determined the correlation of plasma protein levels to clin-
ical parameters upon weight loss (fig. B.22 A-F). Remarkably, the five factors
that showed the most significant correlation with BMI were Complement Factor
H (CFH), C3, APCS, ORM2 and CFI, all inflammatory proteins. Likewise,
other inflammatory proteins including CRP, SAA4, ORM1, Attractin (ATRN)
and CFB also correlated with BMI. Though the link between inflammation and
obesity is well established [110] this analysis of the plasma proteome provides
one of the most comprehensive analyses of the impact of weight loss on inflam-
mation. Alongside known inflammatory factors in obesity like the dipeptidase
ATRN [111], the results show that the described multitude of inflammatory
factors responds to weight reduction, suggesting a systematic reduction in in-
flammation.
Consequently, we wanted to come up with a systemic inflammation profile for
all study participant across the observation period. To this end, we only con-
sidered highly significantly changed proteins (compare fig. B.20) for the Uniprot
keywords „acute phase“, „immunity“ and „inflammatory response“. We also
added the two known acute phase proteins APCS and LBP to our profile list
and excluded the anti-inflammatory protein CD14. Consequently, we arrived at
24 inflammation-related proteins, 20 of which decreased in intensity in the ob-
servation period. Among these, we chose to include all ten proteins that were
significantly correlated with BMI into the protein panel of our inflammation pro-
file. We therefore calculated the standard score for each protein in the panel over
the individual time series and performed a hierarchical clustering on the level of
study participants. The resulting cluster and the heat map of the longitudinal
inflammation profiles for all 42 individuals is displayed in figure (fig. B.22 G).
Before weight reduction the levels of inflammatory proteins in our panel were
high for almost all participants. While some profiles and proteins in the panel
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were immediately reduced following the weight loss, others only decreased gradu-
ally. The trend however is clear across almost all individuals and all proteins
in the panel: Weight reduction leads to a marked decrease in the levels of the
inflammatory proteins in the panel. The study participants clustered in three
main groups. The first group consisting of seven individuals (top in fig. B.22 G)
showed a strong increase in inflammatory proteins in weeks 4 or 13 after weight
loss, probably due to infections following the metabolic changes. The members
of this group did not regain weight in this time period. For example, participant
31 from this group had a 24-fold increase in CRP and a 54-fold increase in SAA1
in week 13 compared to her normal levels of these inflammation markers, point-
ing towards an infection as the cause. The main cluster comprised 72% of the
study participants and is therefore likely to represent the common inflammatory
response to weight loss. Figure B.22 H depicts the changes of the panel proteins
in this group with the median across all panel proteins and individuals shown
in black for each time point. Judged by figure B.22 H it seems that inflam-
mation mostly decreases during weight loss and in the first months of weight
maintenance followed by constantly reduced inflammation levels.
We also wanted to assess for each individual whether inflammation reduced fol-
lowing the body weight reduction. We did so by calculating the mean of all
Z-scored ten panel proteins for each individual for each time point and evaluat-
ing the resulting trend. 39 of the 42 individuals had a negative slope over the
observation period corresponding to beneficial eﬀect on inflammation. Two of
the three individuals, that had a positive slope, actually gained weight in the
observation period and the third individual had elevated inflammation mark-
ers in week 13 and 26, probably due to an infection. Taken together the data
support the theory, that weight reduction can reduce the low grade inflamma-
tion observed in obese individuals. The simultaneous, unbiased measurement
of a multitude of inflammatory molecules in our study provides us with a com-
prehensive and systematic evaluation of inflammatory alterations accompanying
and following weight loss.
B.7 Clinical significance of plasma proteomics changes upon weight loss
The study investigated the eﬀects of eight weeks of weight reduction followed
by one year of weight maintenance in 43 obese individuals by state of the art
MS-based proteomics. The automated sample preparation workflow allows to
quantitatively measure more than thousand samples in a matter of weeks paving
the way for the large scale analysis of clinical studies. This high throughput did
not come at the cost of a drastic reduction of proteome coverage, because the 400
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Figure B.22: Longitudinal profile of inflammatory proteins following acute weight
loss: A-F: Correlation of the indicated clinical parameters with all quantified plasma proteins
plotted against p-values. G: Longitudinal inflammation profiles for all 42 participants across
the entire observation period as judged by a panel of ten inflammatory proteins. The MS-
intensities of the ten panel proteins were Z-transformed for each individual and a hierarchical
clustering was calculated for the individual longitudinal inflammation profiles. H: Dot plot of
the panel proteins in the same order as in G for the central cluster. The median Z-score of the
panel per time point is indicated by the black line. Adapted from [52].
routinely quantified proteins comprised all clinically relevant lipoproteins, many
markers of low grade inflammation and many other functional plasma proteins.
A previous plasma proteomics study with a clinical focus relied on the depletion
of highly abundant plasma proteins and multiplexing to obtain a reasonable pro-
teomic coverage of 190 proteins per sample [112]. While multiplexing appears to
be a promising strategy to further enhance throughput, the unspecific binding
of depletion kits compromises quantitative accuracy. From our quadruplicate
measurements of each sample, we were able to conclude that our protein quanti-
fication was highly reliable. Among other things the longitudinal analysis of such
a large cohort revealed that a surprisingly large proportion of plasma proteins
shows greater variation between individuals than in one individual over time.
The acute weight loss had a profound impact on the levels of multiple plasma
proteins and while some protein levels changed permanently others reverted to
their initial baseline following a short adaptation period. In several cases the
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studied proteins had previously been associated with obesity like CRP, S100-A9
[112] or SERPINF1 [106, 113], but their response to weight loss had not been
studied systematically. Our results on the reduction of SERPINF1 suggest that
it might be a useful indicator for fat mass reduction as opposed to lean mass
reduction.
Most inflammatory proteins and acute phase proteins in particular showed a
marked reduction upon weight loss. Prominent examples were CRP (-35% reduc-
tion) and SAA1 (-44% reduction) both of which are associated with increased risk
for cardiovascular diseases. Their longitudinal behavior clustered together with
functionally related proteins, but also some proteins with no previously known
functional connections, suggesting that some of these proteins might be useful
for the assessment of cardiovascular morbidity. Another prominent group of pro-
teins that was substantially altered by weight loss were apolipoproteins. We re-
corded the expected correlations between LDL, HDL and triglycerides with their
respective apolipoproteins. Combinations of these protein levels might render
fruitful clinical parameters to evaluate the risk of cardiovascular diseases.
Both the inflammatory markers and the apolipoprotein profiles of individuals
suggest, that proteomics might be of clinical use to stratify patients based on
their cardiovascular risks and their potential benefit from weight loss. This could
contribute to a better, more personalized treatment of patients suﬀering from the
metabolic syndrome.
B.8 Materials and Methods of the plasma proteome project
The study design is described in detail in [103]. Briefly, 58 individuals with BMI
between 30 and 40 kg/m2 were enrolled for the study. The exclusion criteria
comprised chronic illness other than obesity, medical treatment aﬀecting glucose
or lipid metabolism, appetite or food intake, pregnancy or breast feeding and
fasting glucose levels above 7 mmol/l. All participants kept a very low calorie
diet (800 kcal per day; Cambridge Weight Plan, Corby, UK [104]) for eight weeks
resulting in a weight loss of at least 7.5%. This period of acute body weight re-
duction was followed by a weight maintenance period of one year with a daily
energy uptake of 600 kcal below the estimated need. Since the study originally
aimed to test the incretin mimetic drug liraglutide, half the study cohort re-
ceived 1.2mg liraglutide after weight loss. Given that both groups were equally
successful in maintaining the weight loss and we could not find significant diﬀer-
ences between their plasma proteomes, we did not distinguish between the two
groups in our analyses. Blood samples were collected before weight loss (week
-8), immediately after (week 0) and at weeks 4, 13, 26, 39 and 52 after weight
loss.
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The ethical committee in Copenhagen approved the study (reference number:
H-4-210-134) and it was conducted in accordance with the Helsinki Declara-
tion II and ICH-GCP practice. All participants were volunteers and had the
possibility to retract their consent at any time. CliniclTrials.gov identifier:
NCT02094183.
Our sample preparation protocol and instrument settings were previously de-
scribed in [54]. An EAYS-nLC 1000 from Thermo Fisher Scientific was used to
separate the purified peptides on a 18-min HPLC gradient prior to the transfer
to a Q Exactive HF Orbitrap (Thermo Fisher Scientific) with identical settings
to [54]. For the construction of our matching library the 20 most abundant
plasma proteins were depleted from the samples of three healthy men and three
healthy women using two immunodepletion kits successively according to the
manufacturer’s protocol (Agilent Multiple Aﬃnity Removal Spin Cartridge and
ProteoPrep20 Plasma Immunodepletion Kit). Upon depletion the samples were
digested and measured in triplicates with identical settings as the non-depleted
samples of the weight loss study, except for the use of 45-min gradient instead
of the 18-min gradient.
MS spectra were analyzed in MaxQuant version 1.5.3.23 [11] using the homo
sapiens Uniprot FASTA database from June 2015. We filtered for contamin-
ants with the predefined contaminants database of the Andromeda search engine
and imposed a FDR of 0.01 on all identified peptides and proteins as described
above. The match between runs feature was used to optimize MS identification
of peptides in the short runs from our deep plasma proteomics matching library.
Label-free protein quantification by the MaxLFQ algorithm [37] used a minimum
ratio count of 1.
Downstream analysis was carried out in Perseus (version 1.5.2.12) [59]. All
hypothesis tests were corrected for multiple hypothesis testing via Benjamini-
Hochberg using a FDR of 5%. A detailed description of the 1 D annotation
enrichment analysis can be found in [60].
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C.1 Additional figures of the saliva proteome project
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Figure C.1: Cumulative benefit of fractionation and MaxQB: A: Cumulative number of
identified human saliva proteins from male donor 1 from eight basic reverse phase fractions.
B: MaxQB protein rank plot for Transcobalamin 1, an important transporter of Vitamin B12.
Adapted from [51].
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Figure C.2: Correlation of plasma proteome and saliva proteome for specific sites:
Scatter plots of LFQ values of shared plasma proteins and slaiva proteins form the parotid
gland (A), the opening of the submandibular and sublingual duct (B) and from gingiva (C).
Adapted from [51].
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Figure C.4: PCA of the human saliva proteome and dynamic range plot of bacterial
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samples separates samples weakly based on sex. B: Dynamic range plot of the bacterial proteins
for the four most abundant phyla. The protein density is color coded. Adapted from [51].
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C.2 PASEF analysis of 40 precursors from a complex peptide mixture
Table A.1: PASEF Analysis of 40 peptides from an equimolar mixture of ADH, BSA,
Enolase and Phosphorylase B: Ten sets of four precursors each were selected for PASEF
Scans in analogy to the experiment in figure A.16 . aMedian summed fragment ion intensities
were extracted for each precursor from PASEF (N=331) and TIMS-MS/MS (N=9) scans
with identical quadrupole isolation settings. bAs an artifact resulting from the asynchronous
operation of TIMS and quadrupole, these two precursors were not isolated in each PASEF
scan. Adapted from [53].
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